var title_f18_57_19344="Centripetal obesity in Cushings";
var content_f18_57_19344=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F50564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F50564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Centipetal obesity in Cushing's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 311px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    30-year-old woman with Cushing's disease showing centripetal obesity, relatively thin limbs, dorsal kyphosis, and thick neck.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Williams Textbook of Endocrinology, 8th ed, Foster, DW, Wilson, JD (Eds), WB Saunders, Philadelphia, 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_57_19344=[""].join("\n");
var outline_f18_57_19344=null;
var title_f18_57_19345="Vulva trauma drain";
var content_f18_57_19345=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair following major vulvar trauma from motor vehicle accident",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Appearance of the wound following closure. Note drain in place due to nature of injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marc Laufer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_57_19345=[""].join("\n");
var outline_f18_57_19345=null;
var title_f18_57_19346="Patient information: Nausea and vomiting with cancer treatment (The Basics)";
var content_f18_57_19346=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/40/1667\">",
"         Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/36/579\">",
"         Patient information: Managing pain when you have cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/57/28562\">",
"         Patient information: Nausea and vomiting in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/32/40450\">",
"         Patient information: Radiation therapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/4/29762\">",
"         Patient information: When your cancer treatment makes you tired (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?20/51/21300\">",
"         Patient information: Complementary and alternative medicine treatments (CAM) for cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/61/32726\">",
"         Patient information: Reducing the costs of medicines (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/nausea-and-vomiting-with-cancer-treatment-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H27993881\">",
"      <span class=\"h1\">",
"       Why might people have nausea and vomiting with cancer treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Nausea and vomiting are common side effects of a cancer treatment called chemotherapy. Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"     </p>",
"     <p>",
"      Not everyone who gets chemotherapy will have nausea and vomiting. Your doctor will tell you how likely it is that you will have these symptoms and how severe they will be.",
"     </p>",
"     <p>",
"      When people have nausea and vomiting after chemotherapy, they usually feel better within 1 to 2 days. But some people have symptoms up to 3 to 4 days after their chemotherapy. This will depend on the type of chemotherapy medicines, dose, and treatment schedule.",
"     </p>",
"     <p>",
"      Another cancer treatment, called radiation therapy, can also cause nausea and vomiting. Not everyone who gets radiation therapy will have nausea and vomiting. It will depend on the part of the body part treated, dose of radiation, and if the person gets chemotherapy at the same time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27993888\">",
"      <span class=\"h1\">",
"       Can nausea and vomiting be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your chemotherapy is likely to cause nausea and vomiting, your doctor will give you medicines before your treatment. These medicines can prevent nausea and vomiting. There are different medicines your doctor can use, and they come in different forms. They can come as a pill, skin patch, or tablet that melts on the tongue, or they can go into your vein. People can get 1 or more medicines.",
"     </p>",
"     <p>",
"      People who are likely to have nausea and vomiting for a few days after chemotherapy might also take these medicines for 2 to 4 days after treatment.",
"     </p>",
"     <p>",
"      If your radiation therapy causes nausea and vomiting, your doctor will prescribe medicine for you to take before each radiation treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27993895\">",
"      <span class=\"h1\">",
"       What can I do to manage my nausea and vomiting?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To manage your symptoms, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Take the medicines your doctor prescribes to prevent nausea and vomiting, even if you feel fine. The best way to manage nausea and vomiting is to prevent it from happening.",
"       </li>",
"       <li>",
"        Make sure to drink enough fluids so that you don&rsquo;t get dehydrated. Dehydration is when the body loses too much water. It can cause people to have dark yellow urine and feel thirsty, tired, dizzy, or confused.",
"       </li>",
"       <li>",
"        Eat 5 or 6 small meals during the day after chemotherapy instead of 3 big ones, especially if you feel queasy.",
"       </li>",
"       <li>",
"        Learn how much to eat or drink before your treatment. Some people feel better when they eat or drink a small amount before treatment. Other people feel better if they don&rsquo;t have any food or drink beforehand.",
"       </li>",
"       <li>",
"        Avoid foods that are spicy, greasy, or &ldquo;heavy.&rdquo; Instead, eat foods that are bland, such as crackers, rice, and toast. Other good food choices are soup broths, clear soda, tea, bananas, chicken (broiled or baked), oatmeal, yogurt (plain or vanilla), pasta, and popsicles.",
"       </li>",
"       <li>",
"        Wait 1 hour after your treatment before you eat or drink.",
"       </li>",
"       <li>",
"        Eat and drink slowly.",
"       </li>",
"       <li>",
"        Ask someone else to cook your food, if the smell of food bothers you.",
"       </li>",
"       <li>",
"        Drink ginger ale or take over-the-counter ginger supplements to settle your stomach.",
"       </li>",
"       <li>",
"        Ask your doctor about an alternative treatment called acupuncture, which might be helpful for some people.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27993902\">",
"      <span class=\"h1\">",
"       When should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Are unable to keep any food or drink in your stomach",
"       </li>",
"       <li>",
"        Vomit up the medicines your doctor gives you to prevent nausea and vomiting",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27993909\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=see_link\">",
"       Patient information: Nausea and vomiting in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=see_link\">",
"       Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=see_link\">",
"       Patient information: Radiation therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=see_link\">",
"       Patient information: When your cancer treatment makes you tired (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=see_link\">",
"       Patient information: Managing pain when you have cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/51/21300?source=see_link\">",
"       Patient information: Complementary and alternative medicine treatments (CAM) for cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       Patient information: Reducing the costs of medicines (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?18/57/19346?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16303 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-99C72D4C66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_57_19346=[""].join("\n");
var outline_f18_57_19346=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27993881\">",
"      Why might people have nausea and vomiting with cancer treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27993888\">",
"      Can nausea and vomiting be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27993895\">",
"      What can I do to manage my nausea and vomiting?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27993902\">",
"      When should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27993909\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/51/21300?source=related_link\">",
"      Patient information: Complementary and alternative medicine treatments (CAM) for cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=related_link\">",
"      Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=related_link\">",
"      Patient information: Nausea and vomiting in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=related_link\">",
"      Patient information: When your cancer treatment makes you tired (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_57_19347="Retinal photoreceptor";
var content_f18_57_19347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retinal photoreceptors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The retina is a multilayer of neurons that line the back of the eye.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jeffrey W Berger Retina Teaching Set. Copyrighted by the Scheie Eye Institute and the University of Pennsylvania.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_57_19347=[""].join("\n");
var outline_f18_57_19347=null;
var title_f18_57_19348="Ezetimibe: Patient drug information";
var content_f18_57_19348=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ezetimibe: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     see \"Ezetimibe: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17844?source=see_link\">",
"     see \"Ezetimibe: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zetia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F169567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ezetrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691406",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower cholesterol and other harmful types of cholesterol in the body.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702096",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ezetimibe or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696863",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 4 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid or limit drinking wine, beer, or mixed drinks to less than 3 drinks a day. Drinking too much alcohol may raise your chance of liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12460 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-109.224.62.197-8A62FE5C28-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_57_19348=[""].join("\n");
var outline_f18_57_19348=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169566\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169567\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016350\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016349\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016354\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016355\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016357\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016352\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016353\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016358\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016359\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=related_link\">",
"      Ezetimibe: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17844?source=related_link\">",
"      Ezetimibe: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_57_19349="Loratadine and pseudoephedrine: Patient drug information";
var content_f18_57_19349=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Loratadine and pseudoephedrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41653?source=see_link\">",
"     see \"Loratadine and pseudoephedrine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/29/17877?source=see_link\">",
"     see \"Loratadine and pseudoephedrine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alavert&trade; Allergy and Sinus [OTC];",
"     </li>",
"     <li>",
"      Claritin-D&reg; 12 Hour Allergy &amp; Congestion [OTC];",
"     </li>",
"     <li>",
"      Claritin-D&reg; 24 Hour Allergy &amp; Congestion [OTC];",
"     </li>",
"     <li>",
"      Loratadine-D 12 Hour [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F190102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Chlor-Tripolon ND&reg;;",
"     </li>",
"     <li>",
"      Claritin&reg; Extra;",
"     </li>",
"     <li>",
"      Claritin&reg; Liberator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702411",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to loratadine, pseudoephedrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11784 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_57_19349=[""].join("\n");
var outline_f18_57_19349=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190101\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190102\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020033\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020035\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020034\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020039\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020040\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020042\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020037\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020038\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020043\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020044\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41653?source=related_link\">",
"      Loratadine and pseudoephedrine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/29/17877?source=related_link\">",
"      Loratadine and pseudoephedrine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_57_19350="Treatment and prognosis of fibromyalgia in children and adolescents";
var content_f18_57_19350=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of fibromyalgia in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/57/19350/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/57/19350/contributors\">",
"     Yukiko Kimura, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/57/19350/contributors\">",
"     Gary A Walco, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/57/19350/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/57/19350/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/57/19350/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/57/19350/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/57/19350/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibromyalgia is one of a group of chronic soft tissue pain disorders that is poorly understood. The etiology and pathogenesis of this disorder are unknown. It is characterized by chronic and diffuse musculoskeletal pain, severe fatigue, and non-restorative sleep. Initially described in adults, this disorder also occurs in children and adolescents, and is often referred to as juvenile primary fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19350/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31031?source=see_link\">",
"     \"Pathogenesis of fibromyalgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of fibromyalgia in children and adolescents will be reviewed here. The clinical manifestation and diagnosis of fibromyalgia in children, and the clinical features, diagnosis, and treatment of the disease in adults are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7896?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link\">",
"     \"Initial treatment of fibromyalgia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A multidisciplinary approach that incorporates physicians, psychologists, and rehabilitation specialists, and that offers a combination of pharmacologic, cognitive-behavioral, and physical interventions, along with patient education, has been shown to be most effective in treating patients with fibromyalgia. Management should begin in a stepwise approach starting with nonpharmacologic interventions. Medications may be added particularly for treating certain aspects of fibromyalgia, such as depression, sleep disturbances, and pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial and sometimes most important therapy for patients with fibromyalgia is to provide them with a diagnosis, education about their illness, and structure for living their life with this chronic disorder. Simply having an actual diagnosis, after months and sometimes years of symptoms and many doctors' visits without a clear answer, is often of help to the patient and family in terms of beginning to understand and cope with the illness.",
"   </p>",
"   <p>",
"    Education and advice on specific areas include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sleep regimen - Because of the prevalence of sleep disturbances in these children, it is important to establish a routine sleep regimen with regular times for waking and going to bed. Caffeine should be avoided, especially from the late afternoon hours onward.",
"     </li>",
"     <li>",
"      School attendance - For children who have avoided school, efforts should be directed towards a return to attending school on a regular basis. Full time school attendance with minimal accommodations is the ultimate goal, although for children with extended absenteeism, the process of achieving this may be a prolonged one. Gradually increasing the number of hours spent in school with appropriate supplementation by at-home tutoring should provide a structure that allows the child to remain on par academically while facilitating a smooth transition back to the classroom.",
"     </li>",
"     <li>",
"      Change in expectations - While it is important that the patient and",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      family maintain hope and optimism, realistic goals will help avoid disappointment and frustration. Thus, at least initially, expectations should focus on improvements in sleep, pain, and daily functioning, which are usually achievable as opposed to the longer term goals of complete alleviation or resolution of symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EXERCISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults with fibromyalgia, strong evidence shows that aerobic exercise has a beneficial effect, resulting in a sense of improved well-being, improved physical functioning, and a reduction in pain and tender points. Preliminary data show similar outcomes in juvenile fibromyalgia, which is supported by our own clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19350/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link&amp;anchor=H352172117#H352172117\">",
"     \"Initial treatment of fibromyalgia in adults\", section on 'Exercise'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link\">",
"     \"Initial treatment of fibromyalgia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PSYCHOLOGIC INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have demonstrated the beneficial effects of cognitive-behavioral therapy (CBT) in improving the symptoms of children with fibromyalgia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a single-blind trial, 114 adolescents with fibromyalgia were randomized to CBT or fibromyalgia education after eight weeks of stable medications [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19350/abstract/6\">",
"       6",
"      </a>",
"      ]. Both groups demonstrated a significant decrease in symptoms of depression and functional disability after eight weeks of therapy and at six-month follow-up, with the latter improving to a significantly greater degree in the CBT group. A significant decrease in pain was not seen in either group.",
"     </li>",
"     <li>",
"      In another controlled trial, thirty adolescents with fibromyalgia were randomly assigned to eight weeks of active pain-coping skills training or self-monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19350/abstract/7\">",
"       7",
"      </a>",
"      ]. Although all patients exhibited lower levels of disability and depressive symptoms after eight weeks than at baseline, those who received coping skills training were better able to cope with pain than were those in the self-monitoring group. Subjects were then crossed over to the opposite treatment arm for eight weeks and were reevaluated at week 16 of the study. All patients had lower levels of disability and depressive symptoms compared to baseline, but those who received self-monitoring followed by coping skills training seemed to receive the most benefit.",
"     </li>",
"     <li>",
"      In one study of 67 children with fibromyalgia, cognitive-behavioral interventions (cognitive restructuring, thought stopping, distraction, relaxation, and self-reward) and",
"      <span class=\"nowrap\">",
"       patient/parent",
"      </span>",
"      education (pain management, psychoeducation, sleep hygiene, and activities of daily living) reduced pain, somatic symptoms, anxiety, fatigue, and school absences, and improved sleep quality and reported functional ability in most patients [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19350/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cohort of seven girls with fibromyalgia, cognitive-behavioral techniques (progressive muscle relaxation and guided imagery) reduced pain and facilitated improved function [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19350/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the use of medications in the treatment of juvenile fibromyalgia are limited. However, agents that have shown beneficial effects in adults also have been used in children, and are sometimes effective. The following is a summary of agents that have been used in children with fibromyalgia. A more complete discussion on the use of each of these classes of medications in adults with fibromyalgia is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial treatment of fibromyalgia in adults\", section on 'Medications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following antidepressants have been used to treat fibromyalgia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tricyclic antidepressants (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/32/7687?source=see_link\">",
"       amitriptyline",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Serotonin-reuptake inhibitors (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/63/33785?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ) and serotonin-norepinephrine-reuptake inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"       milnacipran",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a meta-analysis, these classes of antidepressants were shown to be effective in reducing pain and depression in adults with fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19350/abstract/10\">",
"     10",
"    </a>",
"    ]. Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    have been approved by the US Food and Drug Administration (FDA) to treat symptoms of fibromyalgia syndrome. In addition, tricyclic antidepressants were also beneficial in reducing pain and improving sleep.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most analgesics, including nonsteroidal anti-inflammatory agents and opioids, are ineffective in reducing pain in patients with fibromyalgia. There is some evidence, however, that the combined use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/7/26743?source=see_link\">",
"     tramadol",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    may reduce pain in adults with fibromyalgia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     GABA agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;In randomized clinical trials, gamma amino-butyric acid (GABA) agonists, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/23/35191?source=see_link\">",
"     gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    , help reduce pain in adults with fibromyalgia. Pregabalin was the first drug to be approved by the Food and Drug Administration (FDA) for treatment of fibromyalgia. Whether this drug will be shown to be safe and effective in children remains to be seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Alternative and complementary medicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative or complementary medicine have not, in general, demonstrated sustained benefit in either adults or children with fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19350/abstract/11\">",
"     11",
"    </a>",
"    ]. Traditional Chinese acupuncture does not appear to be significantly more effective in relieving pain in adult patients with fibromyalgia than sham procedures. Data in children are limited to one small observational study of children with chronic pain that reported improved discomfort after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19350/abstract/12\">",
"     12",
"    </a>",
"    ], but there are no data demonstrating its benefit specifically in patients with fibromyalgia. A randomized trial of 66 adult patients with fibromyalgia demonstrated greater improvement in the patients who performed tai chi twice a week for 12 weeks compared with those who performed a non-tai chi exercise program [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19350/abstract/13\">",
"     13",
"    </a>",
"    ]. Whether this complementary approach to fibromyalgia treatment is found to be beneficial in larger numbers of patients, and in children and adolescents with fibromyalgia, remains to be seen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5786?source=see_link&amp;anchor=H22300605#H22300605\">",
"     \"Treatment of fibromyalgia in adults not responsive to initial therapies\", section on 'Acupuncture'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5786?source=see_link&amp;anchor=H22300584#H22300584\">",
"     \"Treatment of fibromyalgia in adults not responsive to initial therapies\", section on 'Complementary and alternative therapies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link\">",
"     \"Initial treatment of fibromyalgia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of specific pediatric studies, we treat children with juvenile fibromyalgia using the evidence based recommendations of the 2008 European League Against Rheumatism (EULAR) guidelines, which are based upon studies of adults with this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19350/abstract/14\">",
"     14",
"    </a>",
"    ]. These guidelines utilize a stepwise patient specific approach, which is individualized for each patient [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19350/abstract/15\">",
"     15",
"    </a>",
"    ]. Initial management primarily focuses on nonpharmacologic measures. If there is an inadequate response, pharmacologic therapy is added.",
"   </p>",
"   <p>",
"    In our practice, management of a child with fibromyalgia includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Therapy starts with confirmation of the diagnosis by a clinician experienced in treating juvenile fibromyalgia. The disease is then reviewed with the patient and",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      family, including its chronic, but generally nonprogressive nature. If there are other disorders present (eg, depression, restless legs syndrome, sleep apnea, and regional musculoskeletal disorders such as bursitis or tendonitis, etc), these should be identified and treated as well. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Education'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low impact aerobic activities such as biking, swimming, or water aerobic exercises are begun and individualized to meet each patient's needs. The level of activities should be set at an initially low level because many patients may have increased pain and low tolerance for exercise, especially since most are deconditioned. It is important to emphasize the necessity of doing regular, daily aerobic exercise to achieve the most benefit. A course of physical therapy with gradual cardiovascular fitness training may help children and adolescents to develop the optimal activity regimen. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Exercise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient is referred for cognitive behavioral therapy, which is most effective if combined with an ongoing exercise program. Treatment should include behavioral interventions to establish more adaptive behavioral routines, including returning to school, facilitating coping and problem solving strategies, and learning self-regulatory techniques to improve pain modulation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Psychologic interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pain control, we usually begin patients on a low dose of a tricyclic antidepressant medication at nighttime, and use simple analgesics (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ) as needed during the day. Nonsteroidal antiinflammatory drugs are not recommended as first-line therapy but may be useful in combination with drugs that affect the central nervous system. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have not responded to the above measures may be considered for the following additional pharmacologic interventions:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Selective serotonin reuptake inhibitors (SSRIs), such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/63/33785?source=see_link\">",
"       fluoxetine",
"      </a>",
"      (dose of 20 to 80",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      or use of a dual selective norepinephrine and serotonin reuptake inhibitors (SNRIs), such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      (initial dose 40 to 60",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"       milnacipran",
"      </a>",
"      (50 to 100 mg twice a day). It should be noted that, for adolescents and children, there is a black box warning for SSRIs and SNRIs because some patients have experienced a worsening of depression with suicidal ideation and behavior. Pediatric patients on these medications should be carefully monitored for this complication. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Antidepressants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other CNS acting agents including",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/23/35191?source=see_link\">",
"       gabapentin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      , particularly in patients who are inadequately treated by or are intolerant of antidepressants. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'GABA agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/7/26743?source=see_link\">",
"       Tramadol",
"      </a>",
"      with or without",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      may be added to assist in pain management. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Analgesics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little is known about the natural course of juvenile fibromyalgia syndrome, especially if left untreated. A number of studies have shown beneficial effects from pharmacologic, psychological, and physical interventions, but there are no follow-up data to determine the long-term impact of these treatments.",
"   </p>",
"   <p>",
"    One study of 59 children (mean age at diagnosis 15.5 years) reported follow-up data at a mean duration of 18.3 months after diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19350/abstract/16\">",
"     16",
"    </a>",
"    ]. Of the 50 patients available for follow-up, disease severity improved in 30 (60 percent), remained unchanged in 18 (36 percent), and worsened in 2 patients (4 percent) compared with their initial presentation. Thirty-seven patients were still taking medications at the end of the follow-up period. Active exercise was associated with a better outcome.",
"   </p>",
"   <p>",
"    However, another study of 35 children with fibromyalgia reported a poorer outcome, as 21 patients (60 percent) had not improved after a mean follow-up of 27 months [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19350/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fibromyalgia, like other chronic conditions, may have a significant deleterious effect on quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19350/abstract/18\">",
"     18",
"    </a>",
"    ]. In a study of 59 children with fibromyalgia, patients self-reported severely impaired physical and psychosocial functioning using the Pediatric Quality of Life (Peds QL) Generic Core Score, PedsQL Multidimensional Fatigue Scale, and PedsQL Rheumatology Module Pain and Hurt Scale. Patients with fibromyalgia reported greater pain and fatigue than pediatric patients with other rheumatologic diseases, and more fatigue when compared to children with cancer. These results demonstrated the significant effect that this disorder can have on an affected child at a single point in time.",
"   </p>",
"   <p>",
"    Finally, there is the question of the trajectory of juvenile fibromyalgia over time. We know very little of the relationship between fibromyalgia in children and the syndrome in adults. Do children with fibromyalgia become adults with fibromyalgia? Do adults with fibromyalgia have a history of the syndrome when they were younger? Retrospective studies with adults tend to be flawed so that specific conclusions regarding antecedent childhood findings cannot be made. A single prospective study found that about 60 percent of 48 young adults diagnosed with juvenile fibromyalgia in childhood or adolescence continued to experience widespread pain, poor sleep, and fatigue after a mean follow-up of 3.67 years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19350/abstract/19\">",
"     19",
"    </a>",
"    ]. Even though the numbers are small, this study suggests that the symptoms of juvenile fibromyalgia are likely to continue into adulthood. Further investigation is needed to determine if there is a relationship between juvenile and adult fibromyalgia, and if so, whether intervention can alter the progression of this disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multidisciplinary team that offers a combination of educational, cognitive-behavioral, physical, and pharmacologic interventions provides optimal management for the care of children with fibromyalgia.",
"   </p>",
"   <p>",
"    We suggest the following management approach that is patient-centered and initially is focused on nonpharmacologic measures (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Management approach'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Confirmation of the diagnosis, education about the illness, and structure for living their life with this chronic disorder (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Education'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Daily low impact aerobic exercise regimen (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Exercise'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Cognitive behavioral therapy (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Psychologic interventions'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      We suggest the initial use of a low dose of a tricyclic antidepressant medication for pain control at nighttime and the use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      as needed during the day (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who do not adequately respond to nonpharmacologic measures and initial pharmacologic therapy, additional medications to consider include selective serotonin reuptake inhibitors, dual selective norepinephrine and serotonin reuptake inhibitors, gamma amino-butyric acid agonists (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/23/35191?source=see_link\">",
"       gabapentin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      ), and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/7/26743?source=see_link\">",
"       tramadol",
"      </a>",
"      with or without",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19350/abstract/1\">",
"      Yunus MB, Masi AT. Juvenile primary fibromyalgia syndrome. A clinical study of thirty-three patients and matched normal controls. Arthritis Rheum 1985; 28:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19350/abstract/2\">",
"      Buskila D. Fibromyalgia in children--lessons from assessing nonarticular tenderness. J Rheumatol 1996; 23:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19350/abstract/3\">",
"      Breau LM, McGrath PJ, Ju LH. Review of juvenile primary fibromyalgia and chronic fatigue syndrome. J Dev Behav Pediatr 1999; 20:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19350/abstract/4\">",
"      Anthony KK, Schanberg LE. Juvenile primary fibromyalgia syndrome. Curr Rheumatol Rep 2001; 3:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19350/abstract/5\">",
"      Stephens S, Feldman BM, Bradley N, et al. Feasibility and effectiveness of an aerobic exercise program in children with fibromyalgia: results of a randomized controlled pilot trial. Arthritis Rheum 2008; 59:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19350/abstract/6\">",
"      Kashikar-Zuck S, Ting TV, Arnold LM, et al. Cognitive behavioral therapy for the treatment of juvenile fibromyalgia: a multisite, single-blind, randomized, controlled clinical trial. Arthritis Rheum 2012; 64:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19350/abstract/7\">",
"      Kashikar-Zuck S, Swain NF, Jones BA, Graham TB. Efficacy of cognitive-behavioral intervention for juvenile primary fibromyalgia syndrome. J Rheumatol 2005; 32:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19350/abstract/8\">",
"      Degotardi PJ, Klass ES, Rosenberg BS, et al. Development and evaluation of a cognitive-behavioral intervention for juvenile fibromyalgia. J Pediatr Psychol 2006; 31:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19350/abstract/9\">",
"      Walco GA, Ilowite NT. Cognitive-behavioral intervention for juvenile primary fibromyalgia syndrome. J Rheumatol 1992; 19:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19350/abstract/10\">",
"      H&auml;user W, Bernardy K, U&ccedil;eyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA 2009; 301:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19350/abstract/11\">",
"      Vohra S, Johnston BC, Cramer K, Humphreys K. Adverse events associated with pediatric spinal manipulation: a systematic review. Pediatrics 2007; 119:e275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19350/abstract/12\">",
"      Zeltzer LK, Tsao JC, Stelling C, et al. A phase I study on the feasibility and acceptability of an acupuncture/hypnosis intervention for chronic pediatric pain. J Pain Symptom Manage 2002; 24:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19350/abstract/13\">",
"      Wang C, Schmid CH, Rones R, et al. A randomized trial of tai chi for fibromyalgia. N Engl J Med 2010; 363:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19350/abstract/14\">",
"      Silber TJ, Majd M. Reflex sympathetic dystrophy syndrome in children and adolescents. Report of 18 cases and review of the literature. Am J Dis Child 1988; 142:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19350/abstract/15\">",
"      Masi AT, White KP, Pilcher JJ. Person-centered approach to care, teaching, and research in fibromyalgia syndrome: justification from biopsychosocial perspectives in populations. Semin Arthritis Rheum 2002; 32:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19350/abstract/16\">",
"      Gedalia A, Garc&iacute;a CO, Molina JF, et al. Fibromyalgia syndrome: experience in a pediatric rheumatology clinic. Clin Exp Rheumatol 2000; 18:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19350/abstract/17\">",
"      Malleson PN, al-Matar M, Petty RE. Idiopathic musculoskeletal pain syndromes in children. J Rheumatol 1992; 19:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19350/abstract/18\">",
"      Varni JW, Burwinkle TM, Limbers CA, Szer IS. The PedsQL as a patient-reported outcome in children and adolescents with fibromyalgia: an analysis of OMERACT domains. Health Qual Life Outcomes 2007; 5:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19350/abstract/19\">",
"      Kashikar-Zuck S, Parkins IS, Ting TV, et al. Controlled follow-up study of physical and psychosocial functioning of adolescents with juvenile primary fibromyalgia syndrome. Rheumatology (Oxford) 2010; 49:2204.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6424 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.131.41.98-2F8CF27215-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_57_19350=[""].join("\n");
var outline_f18_57_19350=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EXERCISE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PSYCHOLOGIC INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Analgesics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GABA agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Alternative and complementary medicine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7896?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=related_link\">",
"      Initial treatment of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31031?source=related_link\">",
"      Pathogenesis of fibromyalgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5786?source=related_link\">",
"      Treatment of fibromyalgia in adults not responsive to initial therapies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_57_19351="Bullous lupus erythematosus pathology";
var content_f18_57_19351=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F86217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F86217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Bullous systemic lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 359px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subepidermal blister with a predominantly neutrophilic dermal infiltrate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Samuel L Moschella, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_57_19351=[""].join("\n");
var outline_f18_57_19351=null;
var title_f18_57_19352="Differential diagnosis of the adnexal mass";
var content_f18_57_19352=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Differential diagnosis of the adnexal mass",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/57/19352/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/57/19352/contributors\">",
"     Mitchel S Hoffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/57/19352/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/57/19352/contributors\">",
"     Howard T Sharp, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/57/19352/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/57/19352/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/57/19352/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/57/19352/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In gynecology, the adnexa refers to the region adjoining the uterus that contains the ovary and fallopian tube, as well as associated vessels, ligaments, and connective tissue. Pathology in this area may also arise from the uterus, bowel, retroperitoneum, or metastatic disease from another site, such as the breast or stomach.",
"   </p>",
"   <p>",
"    A mass in the adnexa may be symptomatic or discovered incidentally. Some will regress spontaneously; others require a surgical procedure for histologic diagnosis and treatment.",
"   </p>",
"   <p>",
"    The differential diagnosis of a woman with an adnexal mass will be reviewed here. Evaluation and management of adnexal masses in women and adnexal masses in children are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link\">",
"     \"Approach to the patient with an adnexal mass\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21033?source=see_link\">",
"     \"Ovarian cysts and neoplasms in infants, children, and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;An adnexal mass may be found in females of all ages, fetuses to the elderly. The reported prevalence varies widely depending upon the population studied and the criteria employed. In a random sample of 335 asymptomatic women aged 25 to 40 years, the point prevalence of an adnexal lesion on ultrasound examination was 7.8 percent (prevalence of ovarian cysts 6.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/1\">",
"     1",
"    </a>",
"    ]. In another series, transvaginal ultrasonography was performed on 8794 asymptomatic postmenopausal women as part of their routine gynecological check-up and 2.5 percent had a simple unilocular adnexal cyst [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distribution of histologic types of adnexal masses in one study of over 600 women is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef52990 \" href=\"UTD.htm?7/63/8188\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/3\">",
"     3",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK OF MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most serious concern when an adnexal mass is discovered is the possibility that it is malignant. Characteristics that increase the likelihood of malignancy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prepubescent or postmenopausal female",
"     </li>",
"     <li>",
"      A complex or solid appearing mass (on imaging)",
"     </li>",
"     <li>",
"      Known genetic predisposition",
"     </li>",
"     <li>",
"      Presence in a woman known to have a nongynecological cancer (eg, breast or gastric cancer)",
"     </li>",
"     <li>",
"      Ascites",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In girls younger than 15 years of age, a high percent of ovarian tumors are malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/4\">",
"     4",
"    </a>",
"    ]. The overall risk of malignancy of an adnexal mass increases with age after menarche and is 6 to 11 percent in premenopausal women and 29 to 35 percent in postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical findings can help in differential diagnosis of a complex mass. As an example, tuboovarian abscess often has a complex sonographic appearance that would be worrisome for malignancy, but the presence of fever, leukocytosis, and pelvic tenderness help to suggest the correct diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36823?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Past medical history is also an important predictive factor in differential diagnosis. A personal history of breast cancer puts the woman at increased risk of malignant involvement of the ovary, either from metastatic disease or primary ovarian cancer; nevertheless, most adnexal masses in such women are benign. As an example, a series of 129 women with breast cancer subsequently diagnosed with an adnexal mass (but no evidence of disseminated disease) reported 113 (88 percent) were benign adnexal cysts, seven (5 percent) were tumors of low malignant potential, seven (5 percent) were epithelial ovarian cancers, and two (2 percent) were metastatic breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ascites can be associated with both benign and malignant processes, but is more common with malignancy. In one series of 125 women with a pelvic mass, the incidence of ascites was 5 out of 57 benign ovarian tumors, 7 out of 12 borderline ovarian tumors, and 41 out of 56 malignant ovarian tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/7\">",
"     7",
"    </a>",
"    ]. Benign pelvic masses that can be associated with ascites include fibromas, endometriomas, struma ovarii, and pelvic tuberculosis. Patients with ascites from hepatic, renal or cardiac disease will usually have elevated CA125 levels, and may also be found to have a pelvic mass, or mesenteric shortening on computed tomography. These patients represent difficult management problems; laparoscopy by a gynecologic oncologist, or with one available, may allow those patients without gynecologic malignancy to be identified with minimally invasive surgery, thereby avoiding the morbidity of laporotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likely etiology of an adnexal mass differs among age groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Infants and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology, diagnosis, and management of ovarian neoplasms from the fetal to adolescent age group are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21033?source=see_link\">",
"     \"Ovarian cysts and neoplasms in infants, children, and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Premenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of an adnexal mass discovered in women of reproductive age is broad, including physiologic or functional cysts, ectopic pregnancy, inflammatory etiologies such as a tuboovarian abscess, endometrioma, benign and malignant ovarian neoplasms, or neoplasms metastatic to the ovary (",
"    <a class=\"graphic graphic_table graphicRef69013 \" href=\"UTD.htm?20/40/21131\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Physiologic/functional cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the process of normal ovulation, a follicle develops to maturity and then ruptures to release an ovum; this is followed by formation and subsequent involution of the corpus luteum. Follicular cysts arise when rupture does not occur and the follicle continues to grow; corpus luteum cysts occur when the corpus luteum fails to involute and continues to enlarge after ovulation (the corpus luteum enlarges for the first six weeks of pregnancy and doubles its prepregnancy size [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/8\">",
"     8",
"    </a>",
"    ]). These cysts are therefore called physiologic or functional. Either type may become hemorrhagic.",
"   </p>",
"   <p>",
"    Follicular cysts appear smooth, thin walled, and unilocular on ultrasound examination (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76189 graphicRef79845 \" href=\"UTD.htm?4/48/4870\">",
"     image 1A-B",
"    </a>",
"    ), while a corpus luteum cyst can look complex and grossly are yellow (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76836 \" href=\"UTD.htm?36/0/36865\">",
"     image 2",
"    </a>",
"    ). Simple cysts &lt;2.5 cm in diameter are considered to be normal physiologic cysts. Although physiologic cysts can become quite large, they still are usually less than 10 cm in size. They are generally asymptomatic, unless bleeding or torsion occurs. Most spontaneously resolve within a few weeks, but some persist for several months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Polycystic ovary syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycystic ovary syndrome (PCOS) should be considered in the reproductive age patient found to have multicystic ovaries by ultrasound examination (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55767 \" href=\"UTD.htm?42/40/43649\">",
"     image 3",
"    </a>",
"    ). The classic phenotype is a woman who is obese, hirsute, and anovulatory. Anovulation is characterized by infrequent but heavy and prolonged menses, and infertility. Ultrasound criteria (used for the Rotterdam criteria) considered to have sufficient specificity and sensitivity to define PCOS are the presence of 12 or more follicles in each ovary measuring 2 to 9 mm in diameter",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased ovarian volume (&gt;10 mL; calculated using the formula 0.5 x length x width x thickness). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Pregnancy-related etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are common causes of an adnexal mass specific to pregnant women:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ectopic pregnancy &mdash; Signs and symptoms suggestive of ectopic pregnancy include a history of a missed menstrual period, abdominopelvic pain, and vaginal bleeding. The presence of an intrauterine pregnancy does not entirely exclude the possibility of an additional ectopic gestation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34184?source=see_link\">",
"       \"Ultrasonography of pregnancy of unknown location\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Theca lutein cysts &mdash; Theca lutein cysts (also called lutein cysts, hyperreactio luteinalis) are luteinized follicle cysts that form as a result of overstimulation from high hCG levels or hypersensitivity to hCG. Bilateral multiseptated cystic adnexal masses in a woman with gestational trophoblastic disease, multiple gestation, ovarian hyperstimulation, or a pregnancy complicated by fetal hydrops are likely to represent theca lutein cysts, rather than malignancy. They can also occur in a normal pregnancy due to hypersensitivity to normal levels of hCG. Most are asymptomatic, but maternal virilization, hyperemesis gravidarum, preeclampsia, or thyroid dysfunction may occur. The cysts gradually resolve weeks to months after the source of hCG is eliminated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18470?source=see_link\">",
"       \"Causes of gestational hyperandrogenism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Corpus luteum of pregnancy &mdash; An early intrauterine pregnancy is always associated with a corpus luteum cyst, which is typically less than 2.5 cm in diameter. However, the corpus luteum may occasionally become enlarged and painful due to hemorrhage.",
"     </li>",
"     <li>",
"      Luteoma &mdash; Luteoma is a nonneoplastic ovarian change associated with pregnancy that can simulate a neoplasm on clinical, gross, or microscopic examination [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/9\">",
"       9",
"      </a>",
"      ]. Luteomas involute spontaneously after delivery or are adequately treated by a conservative surgical approach. The diagnosis should be suspected in the presence of a solid adnexal mass and maternal hirsutism or virilization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18470?source=see_link\">",
"       \"Causes of gestational hyperandrogenism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Inflammatory etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pelvic inflammatory disease (PID) is a common inflammatory cause of adnexal or pelvic masses in this age group. Untreated or undertreated cases of PID result in scarring or \"clubbing\" of the tubal fimbriae. This leads to a collection of either tubal secretions or pus, resulting in a hydrosalpinx or pyosalpinx, respectively. When the ovary is also involved, a tuboovarian abscess or complex can form",
"    <span class=\"nowrap\">",
"     (TOA/TOC)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef60914 \" href=\"UTD.htm?9/18/9509\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Findings of abdominopelvic pain, fever, purulent cervical discharge, and cervical motion tenderness in association with an adnexal mass suggest this diagnosis. A prior history of sexually transmitted disease (STD) is also suggestive. Cervical motion tenderness can be elicited with any cause of acute peritonitis; it is not specific for PID. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nongynecologic inflammatory etiologies of an adnexal mass include an appendiceal or diverticular abscess. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31370?source=see_link\">",
"     \"Acute appendicitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34919?source=see_link\">",
"     \"Clinical manifestations and diagnosis of colonic diverticular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Benign ovarian neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian neoplasms arise from the surface epithelium, germ cells, and sex-cord-stromal tissue and may be benign or malignant. These neoplasms persist unless excised. The histopathologic diagnoses in a series of 656 consecutive women aged 27 to 59 who underwent surgery for a persistent adnexal mass are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef52990 \" href=\"UTD.htm?7/63/8188\">",
"     table 1",
"    </a>",
"    ); 30 percent of the patients were postmenopausal [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common benign ovarian masses are discussed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serous and mucinous cystadenoma &mdash; Serous and mucinous cystadenomas are among the most common benign ovarian neoplasms. They are thin-walled, uni- or multilocular, and range in size from 5 to over 20 cm. Compared to serous cystadenomas, mucinous cystadenomas occur less frequently, are more likely to be multiloculated, are larger (they can attain an enormous size), and are less often bilateral (less than 5 versus 20 to 25 percent).",
"     </li>",
"     <li>",
"      Endometrioma &mdash; An endometrioma is a benign cause of an ovarian mass arising from the growth of ectopic endometrial tissue (",
"      <a class=\"graphic graphic_picture graphicRef71991 \" href=\"UTD.htm?30/8/30849\">",
"       picture 2",
"      </a>",
"      ). Patients with endometriosis often complain of pelvic pain, dysmenorrhea, and dyspareunia. An endometrioma, or \"chocolate cyst,\" appears as a complex mass on ultrasound. It also is a common cause of an elevated CA125 level in the premenopausal patient with an adnexal mass. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5863?source=see_link\">",
"       \"Diagnosis and management of ovarian endometriomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mature cystic teratoma &mdash; The mature cystic teratoma (dermoid cyst) is a benign germ cell tumor and is the most common ovarian tumor in the second and third decades of life [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/11\">",
"       11",
"      </a>",
"      ]. Dermoids can contain elements derived from all three germ cell layers; teeth, hair, and sebum are common components. Patients with these tumors may experience pain secondary to ovarian enlargement, spillage of contents into the peritoneal cavity, or ovarian torsion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A flat plate of the abdomen often reveals calcified components, which helps in the differential diagnosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66911 \" href=\"UTD.htm?37/58/38831\">",
"     image 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65982 \" href=\"UTD.htm?5/42/5797\">",
"     picture 3",
"    </a>",
"    ). Ultrasound usually reveals a complex mass (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77727 graphicRef51762 graphicRef62484 \" href=\"UTD.htm?16/2/16424\">",
"     image 5A-C",
"    </a>",
"    ). The tumors are bilateral in 10 to 15 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=see_link&amp;anchor=H10#H10\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\", section on 'Mature cystic teratoma (dermoid cyst)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Malignant ovarian neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of ovarian malignancy in women of this age group with an adnexal mass ranges from 6 to 11 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/5\">",
"     5",
"    </a>",
"    ]. The majority of primary ovarian tumors are partially cystic and derive from epithelial cells, although they can also arise from other cell types, such as germ cell, sex cord-stromal, and mixed cell types. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .) (Also see individual topic reviews on germ cell and sex cord-stromal tumors of the ovary).",
"   </p>",
"   <p>",
"    The ovary can also be involved by metastatic disease, especially from the gastrointestinal tract (Krukenberg tumor) or breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link&amp;anchor=H13733674#H13733674\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\", section on 'Excluding an extraovarian primary cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Leiomyoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A leiomyoma (fibroid) is a benign neoplasm of smooth muscle origin, which usually arises from the uterus, but may also be found in the broad ligament (",
"    <a class=\"graphic graphic_picture graphicRef73375 \" href=\"UTD.htm?29/28/30147\">",
"     picture 4",
"    </a>",
"    ). Most women with symptomatic fibroids are in their 30s or 40s. Myomas are clinically apparent in approximately 25 percent of reproductive aged women and noted on pathological examination in approximately 80 percent of surgically excised uteri.",
"   </p>",
"   <p>",
"    Patients often present with complaints of pelvic pressure, pain, menorrhagia, and dysmenorrhea. Physical examination usually reveals an enlarged, irregularly shaped uterus that appears as a solid uterine tumor or tumors on ultrasound examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A fibroid arising from the posterior uterus and projecting into the posterior cul-de-sac (pouch of Douglas) or coming from the fundus as a pedunculated mass can be confused with an ovarian neoplasm. Cystic degeneration of a fibroid can result in the appearance of a complex mass on ultrasound (",
"    <a class=\"graphic graphic_picture graphicRef60975 \" href=\"UTD.htm?14/30/14818\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64825 \" href=\"UTD.htm?15/24/15745\">",
"     image 6",
"    </a>",
"    ). This, coupled with the fact that fibroids can cause an elevation in the serum CA125 concentration, results in further concern that the mass may be a malignant ovarian neoplasm.",
"   </p>",
"   <p>",
"    Sarcomatous degeneration of a uterine myoma is rare, with an incidence ranging from 0.4 to 1.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=see_link\">",
"     \"Uterine sarcoma: Classification, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Paraovarian/paratubal cysts and other tubal and broad ligament neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoplasms arising from the fallopian tube or broad ligament are rare. Since the tubes and broad ligaments are not usually visualized on ultrasound examination, the source of these tumors may be erroneously attributed to the ovary or uterus, which are more common sites for neoplasms.",
"   </p>",
"   <p>",
"    The most common findings in this area are simple cysts that originate from the remnants of paramesonephric (m&uuml;llerian) or mesonephric (wolffian) ducts that are present during urogenital embryologic development [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The histology of these lesions may also be mesothelial. Paramesonephric cysts are most common, in particular, the hydatid cyst of Morgagni [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. A hydatid cyst of Morgagni is attached to the tubal fimbriae and contains serous fluid surrounded by a translucent wall.",
"   </p>",
"   <p>",
"    Paratubal or paraovarian cysts may also be neoplastic. In a retrospective study of 59 women who underwent surgery for cystic paraovarian lesions, 75 percent had simple cysts and 25 had neoplastic lesions (seven cystadenomas and eight cystadenofibromas); there were no malignant lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/17\">",
"     17",
"    </a>",
"    ]. Malignant paratubal or paraovarian lesions are rare; a literature review found 14 reports of malignant or borderline paraovarian epithelial tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These cysts are usually discovered incidentally during pelvic sonography or surgery. When paratubal cysts are symptomatic, they most commonly present as dull unilateral pelvic pain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/14\">",
"     14",
"    </a>",
"    ]. There are no data regarding whether these cysts, either benign or malignant, are more common in pre- or postmenopausal women. In women with cysts that appear simple on ultrasound and are &lt;10 cm in diameter, no intervention or continuing surveillance is needed. Women with complex",
"    <span class=\"nowrap\">",
"     paratubal/paraovarian",
"    </span>",
"    cysts should be managed in the same manner as women with complex ovarian cysts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link\">",
"     \"Approach to the patient with an adnexal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Postmenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of ovarian cancer increases with advancing age; at least 30 percent of ovarian masses in women over age 50 are malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, an ovarian mass in a postmenopausal woman should be considered malignant until proven otherwise. Malignant adnexal masses include those of primary ovarian origin; metastatic lesions typically from the endometrium, breast, and gastrointestinal tract; and fallopian tubal carcinomas.",
"   </p>",
"   <p>",
"    Nonmalignant etiologies include many of those also seen in patients of reproductive age, such as cystadenoma, leiomyomata, endometrioma, and hydrosalpinx. Diverticular disease should be considered in the older woman who presents with fever, left-sided pelvic pain, and a pelvic mass on pelvic or ultrasound examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34919?source=see_link\">",
"     \"Clinical manifestations and diagnosis of colonic diverticular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Simple cysts are not uncommon in this age group. They probably represent either persistent",
"    <span class=\"nowrap\">",
"     physiologic/functional",
"    </span>",
"    cysts from the premenopausal period or nonovulatory ovarian activity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/2,19,20\">",
"     2,19,20",
"    </a>",
"    ]. In an ovarian cancer screening trial, more than 15,000 women over 55 years old underwent annual transvaginal sonography for three years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/21\">",
"     21",
"    </a>",
"    ]. Simple cysts were seen in 14 percent of women on the first ultrasound. At one-year follow-up, the incidence of new simple cysts was 8 percent. Among ovaries with one simple cyst at the first screen, 32 percent had no ovarian mass, 62 percent had one or more simple cysts, and 6 percent had a complex or solid mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Ovarian carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of ovarian malignancies are derived from the coelomic epithelium, with papillary cystadenocarcinoma being most common. The mean age at diagnosis is 50 to 60 years. Patients often present with vague gastrointestinal symptoms including dyspepsia, early satiety, anorexia, constipation, and bloating; these nonspecific complaints are associated with advanced disease. Physical findings may include a pleural effusion, abdominal distention with ascites, an abdominopelvic mass, and groin adenopathy. Rectovaginal examination will often reveal nodularity of the posterior cul-de-sac. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pelvic ultrasound findings usually include a complex adnexal mass, either unilateral or bilateral, often accompanied by ascites (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57996 \" href=\"UTD.htm?25/47/26367\">",
"     image 7",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=see_link\">",
"     \"Sonographic differentiation of benign versus malignant adnexal masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Typical intraoperative findings include enlarged nodular ovaries (",
"    <a class=\"graphic graphic_picture graphicRef57353 \" href=\"UTD.htm?17/21/17748\">",
"     picture 6",
"    </a>",
"    ) and diffuse intraperitoneal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Fallopian tubal carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoma of the fallopian tube is a rare cause of an adnexal mass (",
"    <a class=\"graphic graphic_picture graphicRef60557 \" href=\"UTD.htm?20/16/20740\">",
"     picture 7",
"    </a>",
"    ). Patients often present with postmenopausal bleeding and pelvic pain, but many have few or no specific symptoms. Some patients will also present with a profuse, watery, vaginal discharge. Ultrasound evaluation reveals a tubular, \"sausage-shaped\" structure in the adnexa (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70329 \" href=\"UTD.htm?38/16/39170\">",
"     image 8",
"    </a>",
"    ) with neovascularization on Doppler flow. Serum CA125 concentration is often elevated in fallopian tubal carcinoma and is helpful in monitoring patients following primary treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Metastatic carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ovaries and fallopian tubes are common sites of metastasis of endometrial, breast, and some gastrointestinal malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link&amp;anchor=H13733674#H13733674\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\", section on 'Excluding an extraovarian primary cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Benign ovarian cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;High levels of gonadotropins or androgens may cause small epithelial lined structures in the ovary to secrete fluid into their inner cavity and enlarge to become cysts. This is not uncommon, especially in the first few years after menopause [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/2,19,20,22\">",
"     2,19,20,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of a simple unilocular cyst in postmenopausal women ranges from 2.5 to 18 percent, depending upon the population and criteria used (eg, &lt;5 or &lt;10 cm).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 8794 asymptomatic postmenopausal women offered transvaginal sonography at the time of a routine gynecological check-up, 2.5 percent (215 patients) had a simple unilocular adnexal cyst; 84 percent were &le;5 cm and 88 percent were missed on pelvic examination [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/2\">",
"       2",
"      </a>",
"      ]. Complete follow-up information was available for 149 of these patients:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Forty-five women underwent surgery for cyst size &ge;10 cm, CA125 &ge;35",
"      <span class=\"nowrap\">",
"       IU/mL,",
"      </span>",
"      or patient preference and were given the following diagnoses: serous cystadenoma (41), mucinous cystadenoma (three), cystadenofibroma (three), paraovarian cyst (one) and ovarian cancer (one). The ovarian cancer occurred in a 3 cm cyst associated with CA125 of 45",
"      <span class=\"nowrap\">",
"       IU/mL.",
"      </span>",
"     </li>",
"     <li>",
"      Among the 104 patients followed conservatively, 44 percent had cyst resolution (median time to resolution 15 months, range 6 to 54 months), although some of these women subsequently developed new cysts. The remaining patients had persistent cysts throughout the study, with a median follow-up of 48 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A series of 15,106 asymptomatic women &ge;50 years of age reported unilocular ovarian cysts in 18 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/22\">",
"       22",
"      </a>",
"      ]. Approximately 70 percent of these cysts spontaneously resolved, most within three months, but 6.8 percent persisted &gt;12 months. No woman with an isolated unilocular cystic ovarian tumor developed ovarian cancer in the cyst.",
"     </li>",
"     <li>",
"      An autopsy study of 234 postmenopausal women (median age 75) who died of nongynecological disease found ovarian cysts in 36 (15 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19352/abstract/20\">",
"       20",
"      </a>",
"      ]. Cyst size ranged from 5 to 75 mm; all were benign except for one case of bilateral serous cystadenomas of low malignant potential. In addition, 11 women had paraovarian cysts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The low risk of malignancy in these and other studies allows consideration of conservative management of simple unilocular cysts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link\">",
"     \"Approach to the patient with an adnexal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Other etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leiomyomata may persist into the menopausal years, but new myomas typically do not develop.",
"   </p>",
"   <p>",
"    Other causes of an adnexal mass include inflammatory lesions of the gastrointestinal tract (especially diverticulitis and, less often, appendicitis), peritoneal and omental cysts, intraligamentous masses, and various retroperitoneal lesions.",
"   </p>",
"   <p>",
"    The prevalence of diverticular disease in the general population is age-dependent, increasing from less than 5 percent at age 40, to 30 percent by age 60, to 65 percent by age 85. During an episode of diverticulitis, a tender mass is palpable in about 20 percent and abdominal distention is common. Symptoms include fever, abdominal pain (usually left lower quadrant), nausea and vomiting, constipation, diarrhea, and urinary symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34919?source=see_link\">",
"     \"Clinical manifestations and diagnosis of colonic diverticular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31370?source=see_link\">",
"     \"Acute appendicitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/27/39346?source=see_link\">",
"       \"Patient information: Ovarian cysts (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/20/2371?source=see_link\">",
"       \"Patient information: Ovarian cysts (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adnexal masses are common in females from birth to menopause. The etiology is usually a primary process of the ovary or fallopian tube, but may involve the broad ligament, uterus, bowel, or retroperitoneum, or metastatic disease from another site, such as the breast or stomach. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most serious concern when an adnexal mass is discovered is the possibility that it is malignant. Characteristics that increase the likelihood of malignancy include (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk of malignancy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Prepubescent or postmenopausal female",
"     </li>",
"     <li>",
"      A complex or solid appearing mass on ultrasound",
"     </li>",
"     <li>",
"      Presence in a woman known to have a nongynecological cancer (eg, breast or gastric cancer)",
"     </li>",
"     <li>",
"      Ascites",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The differential diagnosis of an adnexal mass is broad and varies according to age and menopausal status (",
"      <a class=\"graphic graphic_table graphicRef69013 \" href=\"UTD.htm?20/40/21131\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Findings on ultrasound examination combined with age and clinical findings help to determine the etiology; however, surgery is often required for diagnosis and therapy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link\">",
"       \"Approach to the patient with an adnexal mass\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19352/abstract/1\">",
"      Borgfeldt C, Andolf E. Transvaginal sonographic ovarian findings in a random sample of women 25-40 years old. Ultrasound Obstet Gynecol 1999; 13:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19352/abstract/2\">",
"      Castillo G, Alc&aacute;zar JL, Jurado M. Natural history of sonographically detected simple unilocular adnexal cysts in asymptomatic postmenopausal women. Gynecol Oncol 2004; 92:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19352/abstract/3\">",
"      Guerriero S, Alcazar JL, Ajossa S, et al. Comparison of conventional color Doppler imaging and power doppler imaging for the diagnosis of ovarian cancer: results of a European study. Gynecol Oncol 2001; 83:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19352/abstract/4\">",
"      Norris HJ, Jensen RD. Relative frequency of ovarian neoplasms in children and adolescents. Cancer 1972; 30:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19352/abstract/5\">",
"      Kinkel K, Lu Y, Mehdizade A, et al. Indeterminate ovarian mass at US: incremental value of second imaging test for characterization--meta-analysis and Bayesian analysis. Radiology 2005; 236:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19352/abstract/6\">",
"      Simpkins F, Zahurak M, Armstrong D, et al. Ovarian malignancy in breast cancer patients with an adnexal mass. Obstet Gynecol 2005; 105:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19352/abstract/7\">",
"      Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian malignancy. Gynecol Oncol 2002; 87:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19352/abstract/8\">",
"      Gilman, J, Stein H. The corpus luteum of pregnancy. Surg Gynecol Obstet 1941; 72:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19352/abstract/9\">",
"      Clement PB. Tumor-like lesions of the ovary associated with pregnancy. Int J Gynecol Pathol 1993; 12:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19352/abstract/10\">",
"      Guerriero S, Alcazar JL, Coccia ME, et al. Complex pelvic mass as a target of evaluation of vessel distribution by color Doppler sonography for the diagnosis of adnexal malignancies: results of a multicenter European study. J Ultrasound Med 2002; 21:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19352/abstract/11\">",
"      Killackey MA, Neuwirth RS. Evaluation and management of the pelvic mass: a review of 540 cases. Obstet Gynecol 1988; 71:319.",
"     </a>",
"    </li>",
"    <li>",
"     Herbst, AL. Neoplastic Diseases of the Uterus. In: Comprehensive Gynecology, Manning, S, Steinborn, E, Salway, J (Eds), Mosby-Year Book, Inc, St Louis 1992. p. 924.",
"    </li>",
"    <li>",
"     Vang R, Wheeler JE. Diseases of the fallopian tube and paratubal region. In: Blaustein's Pathology of the Female Genital Tract, 6th ed., Kurman RJ, Ellenson LH, Ronnett BM.  (Eds), Springer, New York 2011. p.529.",
"    </li>",
"    <li>",
"     Katz, VL. Benign gynecologic lesions: Vulva, vagina, cervix, uterus, oviduct, ovary. In: Comprehensive Gynecology, 5th ed. Katz, VL, Lentz, GM, Lobo, RA, Gershenson, DM (Eds), Mosby Elsevier, Philadelphia 2007. p.452.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19352/abstract/15\">",
"      Savelli L, Ghi T, De Iaco P, et al. Paraovarian/paratubal cysts: comparison of transvaginal sonographic and pathological findings to establish diagnostic criteria. Ultrasound Obstet Gynecol 2006; 28:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19352/abstract/16\">",
"      Samaha M, Woodruff JD. Paratubal cysts: frequency, histogenesis, and associated clinical features. Obstet Gynecol 1985; 65:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19352/abstract/17\">",
"      Smorgick N, Herman A, Schneider D, et al. Paraovarian cysts of neoplastic origin are underreported. JSLS 2009; 13:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19352/abstract/18\">",
"      Terada T. Borderline serous papillary tumor arising in a paraovarian cyst. Eur J Obstet Gynecol Reprod Biol 2010; 150:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19352/abstract/19\">",
"      Valentin L, Skoog L, Epstein E. Frequency and type of adnexal lesions in autopsy material from postmenopausal women: ultrasound study with histological correlation. Ultrasound Obstet Gynecol 2003; 22:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19352/abstract/20\">",
"      D&oslash;rum A, Blom GP, Ekerhovd E, Granberg S. Prevalence and histologic diagnosis of adnexal cysts in postmenopausal women: an autopsy study. Am J Obstet Gynecol 2005; 192:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19352/abstract/21\">",
"      Greenlee RT, Kessel B, Williams CR, et al. Prevalence, incidence, and natural history of simple ovarian cysts among women &gt;55 years old in a large cancer screening trial. Am J Obstet Gynecol 2010; 202:373.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19352/abstract/22\">",
"      Modesitt SC, Pavlik EJ, Ueland FR, et al. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol 2003; 102:594.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3204 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8E53C3882F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_57_19352=[""].join("\n");
var outline_f18_57_19352=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK OF MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Infants and adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Physiologic/functional cysts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Pregnancy-related etiologies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Inflammatory etiologies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Benign ovarian neoplasms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Malignant ovarian neoplasms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Leiomyoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Paraovarian/paratubal cysts and other tubal and broad ligament neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Ovarian carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Fallopian tubal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Metastatic carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Benign ovarian cysts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Other etiologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3204\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3204|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/63/2033\" title=\"diagnostic image 1A\">",
"      Follicular cyst ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/26/32160\" title=\"diagnostic image 1B\">",
"      Follicular cyst2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/0/36865\" title=\"diagnostic image 2\">",
"      Corpus luteum cyst ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/40/43649\" title=\"diagnostic image 3\">",
"      Polycystic ovary ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/58/38831\" title=\"diagnostic image 4\">",
"      Calcifications mature teratoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/23/36208\" title=\"diagnostic image 5A\">",
"      Benign teratoma ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/9/23696\" title=\"diagnostic image 5B\">",
"      Dermoid cyst ovary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/16/23808\" title=\"diagnostic image 5C\">",
"      Dermoid cyst ovary2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/24/15745\" title=\"diagnostic image 6\">",
"      Uterine leiomyoma ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/47/26367\" title=\"diagnostic image 7\">",
"      Ovarian cancer ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/16/39170\" title=\"diagnostic image 8\">",
"      Fallopian tube CA ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3204|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/18/9509\" title=\"picture 1\">",
"      Tuboovarian abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/8/30849\" title=\"picture 2\">",
"      Endometrioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/42/5797\" title=\"picture 3\">",
"      Benign teratoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/28/30147\" title=\"picture 4\">",
"      Multiple uterine leiomyomata",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/30/14818\" title=\"picture 5\">",
"      Degenerated uterine leiomyoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/21/17748\" title=\"picture 6\">",
"      Nodular ovarian malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/16/20740\" title=\"picture 7\">",
"      Fallopian tube carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3204|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/63/8188\" title=\"table 1\">",
"      Histopathology adnexal masses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/40/21131\" title=\"table 2\">",
"      Differential dx adnexal mass",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31370?source=related_link\">",
"      Acute appendicitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=related_link\">",
"      Approach to the patient with an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18470?source=related_link\">",
"      Causes of gestational hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34919?source=related_link\">",
"      Clinical manifestations and diagnosis of colonic diverticular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=related_link\">",
"      Clinical manifestations of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5863?source=related_link\">",
"      Diagnosis and management of ovarian endometriomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=related_link\">",
"      Diagnosis of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36823?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21033?source=related_link\">",
"      Ovarian cysts and neoplasms in infants, children, and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=related_link\">",
"      Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/20/2371?source=related_link\">",
"      Patient information: Ovarian cysts (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/27/39346?source=related_link\">",
"      Patient information: Ovarian cysts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=related_link\">",
"      Sonographic differentiation of benign versus malignant adnexal masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=related_link\">",
"      Treatment of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34184?source=related_link\">",
"      Ultrasonography of pregnancy of unknown location",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=related_link\">",
"      Uterine sarcoma: Classification, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_57_19353="Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5’-nucleotidase, gamma-glutamyl transpeptidase)";
var content_f18_57_19353=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/57/19353/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/57/19353/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/57/19353/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/57/19353/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/57/19353/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/57/19353/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/57/19353/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of blood tests are available that reflect the condition of the liver. The most common tests used in clinical practice include the serum aminotransferases, bilirubin, alkaline phosphatase, albumin, and prothrombin time. These tests are often referred to as \"liver function tests,\" although this term is somewhat misleading since most do not accurately reflect how well the liver is functioning, and abnormal values can be caused by diseases unrelated to the liver. In addition, these tests may be normal in patients who have advanced liver disease.",
"   </p>",
"   <p>",
"    Several specialized tests have also been developed (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32450?source=see_link\">",
"     indocyanine green",
"    </a>",
"    clearance), which, although uncommonly used in clinical practice, can measure specific aspects of hepatic function.",
"   </p>",
"   <p>",
"    Despite their limitations, liver biochemical and function tests have many applications in clinical medicine:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They provide a noninvasive method to screen for the presence of liver disease. The serum aminotransferases, for example, are part of a panel of tests used to screen all blood donors in the United States for the presence of transmissible viruses.",
"     </li>",
"     <li>",
"      They can be used to measure the efficacy of treatments for liver disease (such as immunosuppressant agents for autoimmune hepatitis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40058?source=see_link\">",
"       \"Treatment of autoimmune hepatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      They can be used to monitor the progression of a disease such as viral or alcoholic hepatitis.",
"     </li>",
"     <li>",
"      They can reflect the severity of liver disease, particularly in patients who have cirrhosis. As an example, the Child-Turcotte-Pugh score (Child-Pugh class), which incorporates the prothrombin time and serum bilirubin and albumin concentrations, can predict survival (",
"      <a class=\"graphic graphic_table graphicRef78401 \" href=\"UTD.htm?8/21/8540\">",
"       table 1",
"      </a>",
"      ). Similarly, the Model for End Stage Liver Disease (MELD) score, based in part upon the serum bilirubin, is an accurate predictor of three-month mortality and is used routinely in determining the priority of patients awaiting liver transplantation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=see_link\">",
"       \"Model for End-stage Liver Disease (MELD)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pattern of abnormalities on these tests is more accurate than any of the individual tests. An elevation of serum aminotransferases indicates hepatocellular injury, while an elevation of alkaline phosphatase indicates cholestasis. Recognizing patterns that are consistent with specific diseases can prompt appropriate additional testing.",
"   </p>",
"   <p>",
"    The liver biochemical and function tests that are used commonly in clinical practice and that are used occasionally for specific circumstances can be categorized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tests that detect injury to hepatocytes &ndash; Most of these tests measure the concentration of hepatic enzymes, such as the aminotransferases, in the circulation. These enzymes are normally intracellular but are released when hepatocytes are injured. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21494?source=see_link\">",
"       \"Liver biochemical tests that detect injury to hepatocytes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tests of the liver's capacity to transport organic anions and metabolize drugs &ndash; These tests measure the liver's ability to clear endogenous or exogenous substances from the circulation. The best studies include serum measurements of bilirubin, bile acids, caffeine, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      metabolites, a variety of breath tests, and clearance tests such as bromsulphalein (BSP) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32450?source=see_link\">",
"       indocyanine green",
"      </a>",
"      (ICG).",
"     </li>",
"     <li>",
"      Tests of the liver's biosynthetic capacity &ndash; The most commonly performed tests to assess the biosynthetic capacity of the liver are the serum albumin and the prothrombin time (which requires the presence of clotting factors produced in the liver). Other tests that have been used are the serum concentrations of lipoproteins, ceruloplasmin, ferritin, and alpha-1 antitrypsin.",
"     </li>",
"     <li>",
"      Tests that detect chronic inflammation in the liver, altered immunoregulation, or viral hepatitis &mdash; These tests include the immunoglobulins, hepatitis serologies, and specific autoantibodies. Most of these substances are proteins made by B lymphocytes, not by hepatocytes. However, some are quite specific for certain liver diseases, such as antimitochondrial antibodies in primary biliary cirrhosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The liver contains thousands of enzymes, some of which are also present in serum in very low concentrations. Elevation of an enzyme activity in the serum primarily reflects release from damaged liver cells. Elevation of serum enzyme tests can be grouped into two categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Enzymes that reflect generalized damage to hepatocytes",
"     </li>",
"     <li>",
"      Enzymes that reflect cholestasis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will discuss the serum tests that reflect cholestasis. The other categories of liver function tests and enzymes that reflect generalized damage to hepatocytes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21494?source=see_link\">",
"     \"Liver biochemical tests that detect injury to hepatocytes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ALKALINE PHOSPHATASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alkaline phosphatase refers to a group of enzymes that catalyze the hydrolysis of a large number of organic phosphate esters at an alkaline pH optimum. Although alkaline phosphatase is found in many locations throughout the body, its precise function is not yet known [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/1\">",
"     1",
"    </a>",
"    ]. It appears to have an active role in down-regulating the secretory activities of the intrahepatic biliary epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/2\">",
"     2",
"    </a>",
"    ], detoxifying lipopolysaccharide, and hydrolyzing phosphate esters to generate inorganic phosphate for uptake by various tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/3\">",
"     3",
"    </a>",
"    ]. In bone, the enzyme is involved with calcification. At other sites, it may participate in transport processes.",
"   </p>",
"   <p>",
"    At least three separate genes code for the different alkaline phosphatases that exist in multiple isoenzyme forms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/4\">",
"     4",
"    </a>",
"    ]. Most of the alkaline phosphatase isoenzymes of clinical interest are derived from the liver, bone, first trimester placenta, and kidneys, and are coded for by one gene. They are called tissue unspecific alkaline phosphatase since they have the same immunologic properties and amino acid sequence. Although these alkaline phosphatase isoenzymes catalyze the same reactions, they have different physicochemical properties, which are conferred by carbohydrate and lipid side chains added during posttranslational modification [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second alkaline phosphatase gene codes for third trimester placental and intestinal alkaline phosphatase [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/4\">",
"     4",
"    </a>",
"    ]. The third gene codes for a second type of intestinal alkaline phosphatase.",
"   </p>",
"   <p>",
"    Alkaline phosphatase activity in serum is derived primarily from three sources: liver, bone, and in some patients the intestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. The intestinal contribution (about 10 to 20 percent) is of importance primarily in people with blood groups O and B who are secretors of the ABH red blood cell antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/6\">",
"     6",
"    </a>",
"    ]; it is enhanced by consumption of a fatty meal [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/7,8\">",
"     7,8",
"    </a>",
"    ] and has limited clinical importance.",
"   </p>",
"   <p>",
"    Circulating alkaline phosphatase appears to behave like other serum proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/9\">",
"     9",
"    </a>",
"    ]. Its half-life is seven days, and its clearance from serum is independent of the functional capacity of the liver or the patency of the bile ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/9\">",
"     9",
"    </a>",
"    ]. Its sites of degradation are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism of elevated concentration in hepatobiliary disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased serum alkaline phosphatase is derived from tissues whose metabolism is either functionally disturbed (the obstructed liver) or greatly stimulated (placenta in the third trimester of pregnancy and bone in growing children). Although the cause of elevated serum alkaline phosphatase levels is understood in patients with increased bone or placental isoenzymes, the cause in hepatobiliary disease has been debated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/10\">",
"     10",
"    </a>",
"    ]. Two theories were proposed in the past: the damaged liver regurgitates hepatic alkaline phosphatase back into serum; and the damaged liver, particularly if due to obstructive jaundice, fails to excrete the alkaline phosphatase made in bone, the intestines, and the liver.",
"   </p>",
"   <p>",
"    This long-standing debate has been resolved in favor of the regurgitation of liver alkaline phosphatase into serum. The data supporting this theory are compelling:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Only hepatic alkaline phosphatase is found in the serum of patients with liver disease, particularly cholestasis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The clearance rates of infused placental alkaline phosphatase are the same in patients with bile duct obstruction and healthy controls [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In experimental bile duct obstruction in rats, the entire increase in serum alkaline phosphatase activity is due to the leakage of hepatic alkaline phosphatase into serum [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/12\">",
"       12",
"      </a>",
"      ]. The increased serum activity is paralleled by a striking elevation in hepatic alkaline phosphatase activity and is not accounted for by biliary retention of alkaline phosphatase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the elevation in serum alkaline phosphatase in hepatobiliary disease results from increased de novo synthesis in the liver followed by release into the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/13\">",
"     13",
"    </a>",
"    ]. Retained bile acids appear to play a central role in this process; they induce the synthesis of the enzyme and may cause it to leak into the circulation, perhaps by disruption of hepatic organelles and solubilization of phosphatase bound to such membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The precise manner in which the alkaline phosphatase reaches the circulation is unclear. In some patients with cholestasis, small vesicles that contain many basolateral (sinusoidal) membrane enzymes still bound to these membranes, including alkaline phosphatase, have been found in serum [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely used procedure for determination of serum alkaline phosphatase activity involves measuring the release of p-nitrophenol or phosphate from p-nitrophenylphosphate under specified conditions. The results are expressed in international units",
"    <span class=\"nowrap\">",
"     (IU/L),",
"    </span>",
"    which is the activity of alkaline phosphatase that releases 1 mmol of chromogen or Pi per minute.",
"   </p>",
"   <p>",
"    Alkaline phosphatase isoenzymes can be determined using a variety of techniques. Although the isoenzymes can be separated by electrophoresis, bone and liver isoenzymes differ only slightly in electrophoretic mobility and often overlap if run on the electrophoretic systems used in most clinical laboratories. Separation using polyacrylamide gel slabs is the most reliable method and produces clear-cut separations of the liver, bone, intestinal, and placental isoenzymes. However, this method is not always available. Electrophoresis on cellulose acetate, with the addition of heat inactivation, may accomplish the same purpose [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second method is based upon the observation that alkaline phosphatases from individual tissues differ in their susceptibility to inactivation by heat or 2 mol urea [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/17\">",
"     17",
"    </a>",
"    ]. Placental alkaline phosphatase and an isoenzyme found in certain cancers, the Regan isoenzyme, are fully heat-stable after exposure to a temperature of 56&ordm;C for 15 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/18\">",
"     18",
"    </a>",
"    ]. Thus, the finding of an elevated serum alkaline phosphatase concentration in a patient in whom all the excess activity is in a heat-stable fraction strongly suggests that the placenta or a tumor is the source of the elevated enzyme in serum. Unfortunately, in nonselected patients, this method has many limitations and is not recommended.",
"   </p>",
"   <p>",
"    Because none of these methods is widely available, the most practical approach is to measure other enzymes whose elevation reflects liver disease. These include 5'- nucleotidase and gamma-glutamyl transpeptidase. (See",
"    <a class=\"local\" href=\"#H10\">",
"     '5'-Nucleotidase'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13\">",
"     'Gamma-glutamyl transpeptidase'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major value of the serum alkaline phosphatase in the diagnosis of liver disorders is in the recognition of cholestatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/19\">",
"     19",
"    </a>",
"    ]. However, an elevation in the alkaline phosphatase concentration is a relatively common finding and does not always indicate the presence of hepatobiliary disease (",
"    <a class=\"graphic graphic_algorithm graphicRef78223 \" href=\"UTD.htm?13/25/13727\">",
"     algorithm 1",
"    </a>",
"    ). In addition, normal serum values of alkaline phosphatase vary based upon demographic and clinical circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the 15- to 50-year age group, mean serum alkaline phosphatase activity is somewhat higher in men than in women [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/20\">",
"       20",
"      </a>",
"      ]. In comparison, in individuals over age 60, the enzyme activity of women equals or exceeds that of men [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In children, serum alkaline phosphatase activity is considerably elevated in both sexes, correlates well with the rate of bone growth, and appears to be accounted for by the influx of enzymes from osteoid tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/20,22\">",
"       20,22",
"      </a>",
"      ]. Serum alkaline phosphatase in normal adolescent males may reach mean values three times greater than in normal adults without implying the presence of hepatobiliary disease (",
"      <a class=\"graphic graphic_figure graphicRef56695 \" href=\"UTD.htm?12/30/12783\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/20,23\">",
"       20,23",
"      </a>",
"      ]. Infants and young children occasionally display marked transient elevation of serum alkaline phosphatase activity in the absence of detectable liver or bone disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43989?source=see_link\">",
"       \"Transient hyperphosphatasemia of infancy and early childhood\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients older than 60 have somewhat higher values (up to 1.5 times normal) than younger adults [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/21,24\">",
"       21,24",
"      </a>",
"      ]. The alkaline phosphatase is usually derived from the liver in older men and from bone in postmenopausal women [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Enzyme activity in serum may double late in normal pregnancy, primarily because of an influx from the placenta [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Identifying the source of the elevated isoenzyme is helpful if an elevated serum alkaline phosphatase is the only abnormal finding in an apparently healthy person or if the degree of elevation is higher than expected in the clinical setting. One series evaluated 317 patients in a university hospital who were evaluated for an increased serum alkaline phosphatase level: the source of elevation was the liver and bone in 80 and 18 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/11\">",
"     11",
"    </a>",
"    ]. The remaining patients had either a mixed or an intestinal source.",
"   </p>",
"   <p>",
"    If alkaline phosphatase fractionation is not available, differentiation of the source of elevation can also be accomplished by obtaining additional enzyme tests. The best studied are the serum 5'-nucleotidase and gammaglutamyl transpeptidase (GGT) concentrations (see below); one or the other can be obtained to evaluate an elevated alkaline phosphatase. An older test, leucine aminopeptidase, is now rarely used. These enzyme tests are not elevated in bone disorders, and leucine aminopeptidase and possibly 5'-nucleotidase are not elevated in pregnancy.",
"   </p>",
"   <p>",
"    Thus, an increased serum concentration of these enzymes in nonpregnant patients indicates that an elevated serum alkaline phosphatase is due at least in part to hepatobiliary disease. However, a lack of increased serum 5'-nucleotidase in the presence of an elevated alkaline phosphatase level does",
"    <strong>",
"     not",
"    </strong>",
"    exclude liver disease because these enzymes do not necessarily increase in a parallel manner in early or modest hepatic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=see_link\">",
"     \"Approach to the patient with abnormal liver biochemical and function tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Marked elevation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 75 percent of patients with prolonged cholestasis have serum alkaline phosphatase values increased to four times the upper limit of normal or more. Elevations of this magnitude can occur in a variety of diseases associated with extrahepatic or intrahepatic obstruction, and the extent of the elevation does not distinguish between the two:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obstructive jaundice due to cancer",
"     </li>",
"     <li>",
"      Bile duct stones",
"     </li>",
"     <li>",
"      Sclerosing cholangitis (primary or secondary)",
"     </li>",
"     <li>",
"      Bile duct stricture",
"     </li>",
"     <li>",
"      Drug and toxins associated with cholestasis",
"     </li>",
"     <li>",
"      Primary biliary cirrhosis",
"     </li>",
"     <li>",
"      Liver allograft rejection",
"     </li>",
"     <li>",
"      Infectious hepatobiliary diseases seen in patients with AIDS (eg, CMV or microsporidiosis and tuberculosis with hepatic involvement)",
"     </li>",
"     <li>",
"      Infiltrative liver disease (eg, sarcoidosis, tuberculosis, metastatic malignancy, amyloidosis)",
"     </li>",
"     <li>",
"      Alcoholic hepatitis (rarely) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/27\">",
"       27",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Moderate elevation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesser increases in alkaline phosphates activity, up to three times the upper limit of normal, are nonspecific and occur in all types of liver disease, including viral hepatitis, chronic hepatitis, cirrhosis, infiltrative diseases of the liver, and congestive heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/8,10,28\">",
"     8,10,28",
"    </a>",
"    ]. Elevations in hepatic alkaline phosphatase of this magnitude can also occur in disorders that do not directly involve the liver, such as Hodgkin lymphoma, myeloid metaplasia, intra-abdominal infections, and osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A two- to fourfold elevation in serum alkaline phosphatase levels has been described in several members of a family who had no evidence of bone or liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/29\">",
"     29",
"    </a>",
"    ]. The elevation appeared to be transmitted as an autosomal dominant trait, but the site of the excess alkaline phosphatase could not be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Isolated or disproportionate elevation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated elevations of hepatic alkaline phosphatase or disproportionate elevation compared with other tests, such as the serum aminotransferases and bilirubin, can occur in a number of circumstances including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Partial bile duct obstruction due to gallstones or tumor. The mechanism is unknown but probably represents local areas of bile duct obstruction with induction and leakage into serum of hepatic alkaline phosphatase from these obstructed areas.",
"     </li>",
"     <li>",
"      Early in the course of some cholestatic liver diseases such as primary sclerosing cholangitis and primary biliary cirrhosis.",
"     </li>",
"     <li>",
"      Infiltrative diseases such as amyloidosis, sarcoidosis, hepatic abscesses, tuberculosis, and metastatic carcinoma.",
"     </li>",
"     <li>",
"      Ischemic cholangiopathy.",
"     </li>",
"     <li>",
"      Extrahepatic diseases such as myeloid metaplasia, peritonitis, diabetes mellitus, subacute thyroiditis, uncomplicated gastric ulcer, and sepsis. The increase in alkaline phosphatase in these disorders is thought to be related to hepatic dysfunction despite the absence of overt liver disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Extrahepatic tumors, including osteosarcomas, lung, gastric, head and neck, renal cell carcinoma, ovarian, uterine cancer, and Hodgkin lymphoma, that secrete alkaline phosphatase (often a form known as the Regan isoenzyme) or cause leakage of hepatic alkaline phosphatase into serum by an unknown mechanism [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/11,31\">",
"       11,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Certain drugs such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Infants and young children occasionally display marked transient elevation of serum alkaline phosphatase activity in the absence of detectable liver or bone disease. The hyperphosphatasemia typically includes elevations in both bone and liver isoenzymes, and appears to be caused by delayed clearance of the enzyme. The clinical presentation and evaluation of an infant or child with this finding is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43989?source=see_link\">",
"       \"Transient hyperphosphatasemia of infancy and early childhood\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Subnormal values",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extremely low serum alkaline phosphatase concentrations can be seen in patients with fulminant Wilson's disease complicated by hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link\">",
"     \"Tests used in the diagnosis of Wilson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Low values can also occur in patients with hypothyroidism, pernicious anemia, zinc deficiency, congenital hypophosphatemia, and certain types of progressive familial intrahepatic cholestasis in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13387949\">",
"    <span class=\"h3\">",
"     Non-hepatic alkaline phosphatase",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, bone is the most likely source of isolated plasma alkaline phosphatase that is not of liver origin (in nonpregnant patients). An elevated bone alkaline phosphatase is indicative of high bone turnover, which may be caused by several disorders including healing fractures, osteomalacia, hyperparathyroidism, hyperthyroidism, Paget disease of bone, osteogenic sarcoma, and bone metastases. We generally refer such patients to an endocrinologist for evaluation. Initial testing may include measurement of serum calcium, parathyroid hormone, 25-hydroxy vitamin D, and imaging with bone scintigraphy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42519?source=see_link&amp;anchor=H5#H5\">",
"     \"Bone physiology and biochemical markers of bone turnover\", section on 'Markers of bone turnover'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7978?source=see_link&amp;anchor=H16031905#H16031905\">",
"     \"Clinical manifestations and diagnosis of Paget disease of bone\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11416?source=see_link&amp;anchor=H29575819#H29575819\">",
"     \"Clinical manifestations, diagnosis, and treatment of osteomalacia\", section on 'Diagnosis and evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intestinal alkaline phosphatase has multiple biological functions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/3,34\">",
"     3,34",
"    </a>",
"    ]. As noted above, elevated levels in serum are usually of no clinical importance. They are most often found postprandially after a fatty meal and tend to run in families, suggesting that there may be a genetic basis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/35\">",
"     35",
"    </a>",
"    ]. Because elevation is nonspecific, it should not prompt evaluation for a particular intestinal disorder. Normalization of the level while fasting can help reassure that its origin is intestinal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     5'-NUCLEOTIDASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;5'-Nucleotidase is found in the liver, intestine, brain, heart, blood vessels, and endocrine pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/36\">",
"     36",
"    </a>",
"    ]. Although its physiologic function is unknown, 5'-nucleotidase specifically catalyzes hydrolysis of nucleotides such as adenosine 5'-phosphate and inosine 5'-phosphate, in which the phosphate is attached to the 5 position of the pentose moiety.",
"   </p>",
"   <p>",
"    Similar to alkaline phosphatase, 5'-nucleotidase has a subcellular location in hepatocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/37\">",
"     37",
"    </a>",
"    ]. It is bound to bile canalicular and sinusoidal membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/38\">",
"     38",
"    </a>",
"    ] and must be solubilized, perhaps via the detergent action of bile acids, to gain access to the circulation. In experimental bile duct obstruction in rats, bile acid concentrations rapidly reach levels sufficient to disrupt plasma membranes and solubilize the enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/39\">",
"     39",
"    </a>",
"    ]. The same phenomenon may occur in hepatobiliary disorders in which there is any degree of cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum 5'-nucleotidase activity is most commonly assayed by measuring the release of inorganic phosphate using 5'-phosphate as a substrate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/40\">",
"     40",
"    </a>",
"    ]. A unit of 5'-nucleotidase activity is designated as equivalent to that amount of enzyme that liberates 1 mg of phosphate per 100 mL of serum per hour (1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    per hour). These units are analogous to the old Bodansky units of alkaline phosphatase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/41\">",
"     41",
"    </a>",
"    ]. The presence of alkaline phosphatase in serum complicates the assay because it also hydrolyzes the 5'-nucleotide substrates, and corrections must be made for its activity.",
"   </p>",
"   <p>",
"    In most series of normal adults, the serum 5'-nucleotidase concentration ranges from 0.3 to 3.2 Bodansky units and is not clearly influenced by gender or race [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Values are substantially lower in children than in adults, rise gradually in adolescence, and reach a plateau after age 50 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevations in serum 5'-nucleotidase are seen in the same types of hepatobiliary diseases associated with an increased serum alkaline phosphatase. Most studies suggest that serum alkaline phosphatase and 5'-nucleotidase are equally valuable in demonstrating biliary obstruction or hepatic infiltrative and space-occupying lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/43,45\">",
"     43,45",
"    </a>",
"    ]. Although values of the two enzymes are generally correlated, the concentrations may not rise proportionately in individual patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/42,46\">",
"     42,46",
"    </a>",
"    ]. Thus, in selected patients, one enzyme may be elevated and the other normal.",
"   </p>",
"   <p>",
"    Conflicting data have been reported for serum 5'-nucleotidase activity during normal pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. In contrast, most studies show that serum 5'-nucleotidase does not rise in bone disease, [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/49\">",
"     49",
"    </a>",
"    ] and in the few instances in which an increase was observed, it was of low magnitude [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the major value of the 5'-nucleotidase assay is its specificity for hepatobiliary disease. An increased serum 5'-nucleotidase concentration in a nonpregnant person suggests that a concomitantly increased serum alkaline phosphatase is of hepatic origin. However, because of the occasional dissociation between the two enzymes, a normal serum 5'-nucleotidase does not rule out the liver as the source of an elevated serum alkaline phosphatase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     GAMMA-GLUTAMYL TRANSPEPTIDASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gamma-glutamyl transpeptidase (GGT) catalyzes the transfer of the gamma-glutamyl group from gamma-glutamyl peptides such as glutathione to other peptides and to L-amino acids. GGT is present in cell membranes in many tissues, including the kidneys, pancreas, liver, spleen, heart, brain, and seminal vesicles [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/50\">",
"     50",
"    </a>",
"    ]. It is thought to play a role in amino acid transport [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enzyme activity is most commonly assayed using gamma-L-glutamyl-r-nitroanilide as a substrate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/52\">",
"     52",
"    </a>",
"    ]. The liberated product, (chromogen r-nitroaniline) can be measured spectrophotometrically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Clinical significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;GGT is present in the serum of healthy individuals. The normal range is 0 to 30",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    (0 to 0.5",
"    <span class=\"nowrap\">",
"     mkat/L).",
"    </span>",
"    Most studies have found values to be comparable in men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/53,54\">",
"     53,54",
"    </a>",
"    ], although some reports have noted higher values in men [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/55\">",
"     55",
"    </a>",
"    ]. Newborn infants have serum GGT activity six to seven times the upper limit of the adult reference range; levels decline and reach adult levels by five to seven months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/56\">",
"     56",
"    </a>",
"    ]. Serum enzyme activity does not rise during the course of normal pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevated serum activity is found in diseases of the liver, biliary tract, and pancreas, and reflects the same spectrum of hepatobiliary disease as alkaline phosphatase, 5'-nucleotidase, and leucine aminopeptidase. Serum GGT and alkaline phosphatase correlate reasonably well. There are conflicting data as to whether serum GGT has better sensitivity for hepatobiliary disease than alkaline phosphatase or leucine aminopeptidase [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/54,57\">",
"     54,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with serum 5'-nucleotidase, the major clinical value of serum GGT is in conferring organ specificity to an elevated value for alkaline phosphatase since GGT activity is not increased in patients with bone disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/54\">",
"     54",
"    </a>",
"    ]. However, an elevation in serum GGT is not completely specific for hepatobiliary disease. High serum GGT values are found in people who take medicines such as barbiturates or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/58\">",
"     58",
"    </a>",
"    ] or ingest large quantities of alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/59\">",
"     59",
"    </a>",
"    ] even when values for other serum enzyme tests and serum bilirubin are normal. In these settings, there is no correlation between the serum GGT and alkaline phosphatase [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An isolated elevation in serum GGT or a GGT elevation out of proportion to that of other enzymes (such as the alkaline phosphatase and alanine aminotransferase) may be an indicator of alcohol abuse or alcoholic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/60\">",
"     60",
"    </a>",
"    ]. The reasons for this are not well understood. Although hepatic microsomal GGT may be induced by alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/61\">",
"     61",
"    </a>",
"    ], neither elevated serum GGT nor a history or recent alcohol ingestion correlates with hepatic GGT activity in patients with biopsy-proven alcoholic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. In vitro studies suggest an alternative mechanism: alcohol may cause the leakage of GGT from hepatocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aside from its value in conferring liver specificity to an elevated serum alkaline phosphatase level and its possible use in identifying patients with alcohol abuse, serum GGT offers no advantage over aminotransferases and alkaline phosphatase. In one prospective study that included 1040 nonselected inpatients, 13 percent had an elevated serum GGT activity; only 32 percent had hepatobiliary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19353/abstract/64\">",
"     64",
"    </a>",
"    ]. In the remaining patients, the elevated serum GGT may have been due to alcohol ingestion or medications, which caused a temporary rise in levels but without liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alkaline phosphatase refers to a group of enzymes that catalyze the hydrolysis of a large number of organic phosphate esters at an alkaline pH optimum. Although alkaline phosphatase is found in many locations throughout the body, its precise function is not yet known.",
"     </li>",
"     <li>",
"      The major value of the serum alkaline phosphatase in the diagnosis of liver disorders is in the recognition of cholestatic disease. However, an elevation in the alkaline phosphatase concentration is a relatively common finding and does not always indicate the presence of hepatobiliary disease. The degree of elevation does not distinguish between intra- and extra-hepatic cholestasis (",
"      <a class=\"graphic graphic_algorithm graphicRef78223 \" href=\"UTD.htm?13/25/13727\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=see_link\">",
"       \"Approach to the patient with abnormal liver biochemical and function tests\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Elevations in serum 5'-nucleotidase are seen in the same types of hepatobiliary diseases associated with an increased serum alkaline phosphatase. Most studies suggest that serum alkaline phosphatase and 5'-nucleotidase are equally valuable in demonstrating biliary obstruction or hepatic infiltrative and space-occupying lesions.",
"     </li>",
"     <li>",
"      Elevated serum levels of gamma-glutamyl transpeptidase are found in diseases of the liver, biliary tract, and pancreas, and reflect the same spectrum of hepatobiliary disease as alkaline phosphatase, 5'-nucleotidase, and leucine aminopeptidase. Serum GGT and alkaline phosphatase correlate reasonably well. There are conflicting data as to whether serum GGT has better sensitivity for hepatobiliary disease than alkaline phosphatase or leucine aminopeptidase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24932939\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's past work as an author for this topic, as well as his work as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/1\">",
"      Kaplan MM. Alkaline phosphatase. Gastroenterology 1972; 62:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/2\">",
"      Alvaro D, Benedetti A, Marucci L, et al. The function of alkaline phosphatase in the liver: regulation of intrahepatic biliary epithelium secretory activities in the rat. Hepatology 2000; 32:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/3\">",
"      Bates JM, Akerlund J, Mittge E, Guillemin K. Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to the gut microbiota. Cell Host Microbe 2007; 2:371.",
"     </a>",
"    </li>",
"    <li>",
"     Sussman HH. Structural analysis of human alkaline phosphatase. In: Human alkaline phosphatase, Stigbrand T, Fisher WH (Eds), Alan R Liss, New York 1984. p.87.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/5\">",
"      Kaplan MM. Alkaline phosphatase. N Engl J Med 1972; 286:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/6\">",
"      Cho SR, Lim YA, Lee WG. Unusually high alkaline phosphatase due to intestinal isoenzyme in a healthy adult. Clin Chem Lab Med 2005; 43:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/7\">",
"      BAMFORD KF, HARRIS H, LUFFMAN JE, et al. SERUM-ALKALINE-PHOSPHATASE AND THE ABO BLOOD-GROUPS. Lancet 1965; 1:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/8\">",
"      Posen S. Alkaline phosphatase. Ann Intern Med 1967; 67:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/9\">",
"      Clubb JS, Neale FC, Posen S. The behavior of infused human placental alkaline phosphatase in human subjects. J Lab Clin Med 1965; 66:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/10\">",
"      GUTMAN AB. Serum alkaline phosphatase activity in diseases of the skeletal and hepatobiliary systems. A consideration of the current status. Am J Med 1959; 27:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/11\">",
"      Brensilver HL, Kaplan MM. Significance of elevated liver alkaline phosphatase in serum. Gastroenterology 1975; 68:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/12\">",
"      Kaplan MM, Righetti A. Induction of rat liver alkaline phosphatase: the mechanism of the serum elevation in bile duct obstruction. J Clin Invest 1970; 49:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/13\">",
"      Kaplan MM. Serum alkaline phosphatase--another piece is added to the puzzle. Hepatology 1986; 6:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/14\">",
"      Hatoff DE, Hardison WG. Induced synthesis of alkaline phosphatase by bile acids in rat liver cell culture. Gastroenterology 1979; 77:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/15\">",
"      De Broe ME, Borgers M, Wieme RJ. The separation and characterization of liver plasma membrane fragments circulating in the blood of patients with cholestasis. Clin Chim Acta 1975; 59:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/16\">",
"      POSEN S, NEALE FC, CLUBB JS. HEAT INACTIVATION IN THE STUDY OF HUMAN ALKALINE PHOSPHATASES. Ann Intern Med 1965; 62:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/17\">",
"      Bahr M, Wilkinson JH. Urea as a selective inhibitor of human tissue alkaline phosphatases. Clin Chim Acta 1967; 17:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/18\">",
"      ARIAS IM, WOLFSON S, LUCEY JF, MCKAY RJ Jr. TRANSIENT FAMILIAL NEONATAL HYPERBILIRUBINEMIA. J Clin Invest 1965; 44:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/19\">",
"      Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000; 342:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/20\">",
"      Clarke, LC, Beck, E. Plasma \"alkaline\" phosphatase activity. I. Normative data for growing children. J Pediatr 1960; 36:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/21\">",
"      Kuwana T, Sugita O, Yakata M. Reference limits of bone and liver alkaline phosphatase isoenzymes in the serum of healthy subjects according to age and sex as determined by wheat germ lectin affinity electrophoresis. Clin Chim Acta 1988; 173:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/22\">",
"      Kattwinkel J, Taussig LM, Statland BE, Verter JI. The effects of age on alkaline phosphatase and other serologic liver function tests in normal subjects and patients with cystic fibrosis. J Pediatr 1973; 82:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/23\">",
"      Salz JL, Daum F, Cohen MI. Serum alkaline phosphatase activity during adolescence. J Pediatr 1973; 82:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/24\">",
"      HEINO AE, JOKIPII SG. Serum alkaline phosphatase levels in the aged. Ann Med Intern Fenn 1962; 51:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/25\">",
"      Birkett DJ, Done J, Neale FC, Posen S. Serum alkaline phosphatase in pregnancy; an immunological study. Br Med J 1966; 1:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/26\">",
"      Connell MD, Dinwoodie AJ. Diagnostic use of serum alkaline phosphatase isoenzymes and 5-nucleotidase. Clin Chim Acta 1970; 30:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/27\">",
"      Perrillo RP, Griffin R, DeSchryver-Kecskemeti K, et al. Alcoholic liver disease presenting with marked elevation of serum alkaline phosphatase. A combined clinical and pathological study. Am J Dig Dis 1978; 23:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/28\">",
"      Boyde TRC, Latner AL. Starch gel electrophoresis of transaminase in human tissue extracts and serum. Biochem J 1961; 82:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/29\">",
"      Wilson JW. Inherited elevation of alkaline phosphatase activity in the absence of disease. N Engl J Med 1979; 301:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/30\">",
"      Dalovisio JR, Blonde L, Cortez LM, Pankey GA. Subacute thyroiditis with increased serum alkaline phosphatase. Ann Intern Med 1978; 88:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/31\">",
"      Fishman WH. Immunologic and biochemical approaches to alkaline phosphatase isoenzyme analysis: the Regan isoenzyme. Ann N Y Acad Sci 1969; 166:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/32\">",
"      Shaver WA, Bhatt H, Combes B. Low serum alkaline phosphatase activity in Wilson's disease. Hepatology 1986; 6:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/33\">",
"      Berman DH, Leventhal RI, Gavaler JS, et al. Clinical differentiation of fulminant Wilsonian hepatitis from other causes of hepatic failure. Gastroenterology 1991; 100:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/34\">",
"      Lall&egrave;s JP. Intestinal alkaline phosphatase: multiple biological roles in maintenance of intestinal homeostasis and modulation by diet. Nutr Rev 2010; 68:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/35\">",
"      Siraganian PA, Mulvihill JJ, Mulivor RA, Miller RW. Benign familial hyperphosphatasemia. JAMA 1989; 261:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/36\">",
"      Goldberg DM. 5'nucleotidase: recent advances in cell biology, methodology and clinical significance. Digestion 1973; 8:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/37\">",
"      Righetti A, Kaplan MM. Disparate responses of serum and hepatic alkaline phosphatase and 5' nucleotidase to bile duct obstruction in the rat. Gastroenterology 1972; 62:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/38\">",
"      Song CS, Kappas A, Bodansky O. 5'-nucleotidase of plasma membranes of the rat liver: studies on subcellular distribution. Ann N Y Acad Sci 1969; 166:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/39\">",
"      Schlaeger R, Haux P, Kattermann R. Studies on the mechanism of the increase in serum alkaline phosphatase activity in cholestasis: significance of the hepatic bile acid concentration for the leakage of alkaline phosphatase from rat liver. Enzyme 1982; 28:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/40\">",
"      Campbell DM. Determination of 5'-nucleotidase in blood serum. Biochem J 1962; 82:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/41\">",
"      YOUNG II. Serum 5-nucleotidase; characterization and evaluation in disease states. Ann N Y Acad Sci 1958; 75:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/42\">",
"      BARDAWILL C, CHANG C. SERUM LACTIC DEHYDROGENASE, LEUCINE AMINOPEPTIDASE AND 5-NUCLEOTIDASE ACTIVITIES: OBSERVATION IN PATIENTS WITH CARCINOMA OF THE PANCREAS AND HEPATOBILIARY DISEASE. Can Med Assoc J 1963; 89:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/43\">",
"      Hill PG, Sammons HG. An assessment of 5'-nucleotidase as a liver-function test. Q J Med 1967; 36:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/44\">",
"      Belfield A, Goldberg DM. Normal ranges and diagnostic value of serum 5'nucleotidase and alkaline phosphatase activities in infancy. Arch Dis Child 1971; 46:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/45\">",
"      KOWLESSAR OD, HAEFFNER LJ, RILEY EM, SLEISENGER MH. Comparative study of serum leucine aminopeptidase, 5-nucleotidase and non-specific alkaline phosphatase in diseases affecting the pancreas, hepatobiliary tree and bone. Am J Med 1961; 31:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/46\">",
"      Eschar J, Rudzki C, Zimmerman HJ. Serum levels of 5'-nucleotidase in disease. Am J Clin Pathol 1967; 47:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/47\">",
"      Kater RM, Mistilis SP. Obstetric cholestasis and pruritus of pregnancy. Med J Aust 1967; 1:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/48\">",
"      Seitanidis B, Moss DW. Serum alkaline phosphatase and 5'-nucleotidase levels during normal pregnancy. Clin Chim Acta 1969; 25:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/49\">",
"      HUNTON DB, BOLLMAN JL, HOFFMAN HN 2nd. The plasma removal on indocyanine green and sulfobromophthalein: effect of dosage and blocking agents. J Clin Invest 1961; 40:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/50\">",
"      Goldberg DM. Structural, functional, and clinical aspects of gamma-glutamyltransferase. CRC Crit Rev Clin Lab Sci 1980; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/51\">",
"      Meister A. The gamma-glutamyl cycle. Diseases associated with specific enzyme deficiencies. Ann Intern Med 1974; 81:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/52\">",
"      Szasz G. A kinetic photometric method for serum gamma-glutamyl transpeptidase. Clin Chem 1969; 15:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/53\">",
"      ARONSEN KF, HANSON A, NOSSLIN B. THE VALUE OF GAMMA-GLUTAMYL TRANSPEPTIDASE IN DIFFERENTIATING VIRAL HEPATITIS FROM OBSTRUCTIVE JAUNDICE. A STATISTICAL COMPARISON WITH ALKALINE PHOSPHATASE. Acta Chir Scand 1965; 130:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/54\">",
"      Lum G, Gambino SR. Serum gamma-glutamyl transpeptidase activity as an indicator of disease of liver, pancreas, or bone. Clin Chem 1972; 18:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/55\">",
"      RUTTENBURG AM, GOLDBARG JA, PINEDA EP. SERUM GAMMA-GLUTAMYL TRANSPEPTIDASE ACTIVITY IN HEPATOBILIARY PANCREATIC DISEASE. Gastroenterology 1963; 45:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/56\">",
"      Cabrera-Abreu JC, Green A. Gamma-glutamyltransferase: value of its measurement in paediatrics. Ann Clin Biochem 2002; 39:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/57\">",
"      Betro MG, Oon RC, Edwards JB. Gamma-glutamyl transpeptidase in diseases of the liver and bone. Am J Clin Pathol 1973; 60:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/58\">",
"      Rosalki SB, Tarlow D, Rau D. Plasma gamma-glutamyl transpeptidase elevation in patients receiving enzyme-inducing drugs. Lancet 1971; 2:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/59\">",
"      Lamy J, Baglin MC, Ferrant JP, Weill J. [Decrease in serum gamma-glutamyltranspeptidase following abstention from alcohol]. Clin Chim Acta 1974; 56:169.",
"     </a>",
"    </li>",
"    <li>",
"     Kaplan MM, et al. Biochemical basis for serum enzyme abnormalities in alcoholic liver disease. In: Early identification of alcohol abuse, Research Monograph No. 17, Chang NC, Chan NM (Eds), NIAAA, 1985. p.186.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/61\">",
"      Barouki R, Chobert MN, Finidori J, et al. Ethanol effects in a rat hepatoma cell line: induction of gamma-glutamyltransferase. Hepatology 1983; 3:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/62\">",
"      Ivanov E, Adjarov D, Etarska M, et al. Elevated liver gamma-glutamyl transferase in chronic alcoholics. Enzyme 1980; 25:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/63\">",
"      Selinger MJ, Matloff DS, Kaplan MM. gamma-Glutamyl transpeptidase activity in liver disease: serum elevation is independent of hepatic GGTP activity. Clin Chim Acta 1982; 125:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19353/abstract/64\">",
"      Burrows S, Feldman W, McBride F. Serum gamma-glutamyl transpeptidase. Evaluation in screening of hospitalized patients. Am J Clin Pathol 1975; 64:311.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3612 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-2AD339225F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_57_19353=[""].join("\n");
var outline_f18_57_19353=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ALKALINE PHOSPHATASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism of elevated concentration in hepatobiliary disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical significance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Marked elevation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Moderate elevation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Isolated or disproportionate elevation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Subnormal values",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13387949\">",
"      - Non-hepatic alkaline phosphatase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      5'-NUCLEOTIDASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      GAMMA-GLUTAMYL TRANSPEPTIDASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Clinical significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24932939\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3612\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3612|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?13/25/13727\" title=\"algorithm 1\">",
"      Evaluation alkaline phosphatase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3612|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/30/12783\" title=\"figure 1\">",
"      Alk phos range child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3612|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/21/8540\" title=\"table 1\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42519?source=related_link\">",
"      Bone physiology and biochemical markers of bone turnover",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7978?source=related_link\">",
"      Clinical manifestations and diagnosis of Paget disease of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11416?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21494?source=related_link\">",
"      Liver biochemical tests that detect injury to hepatocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=related_link\">",
"      Tests used in the diagnosis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43989?source=related_link\">",
"      Transient hyperphosphatasemia of infancy and early childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40058?source=related_link\">",
"      Treatment of autoimmune hepatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_57_19354="Chemoprophylaxis for the prevention of neonatal group B streptococcal disease";
var content_f18_57_19354=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/57/19354/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/57/19354/contributors\">",
"     Carol J Baker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/57/19354/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/57/19354/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/57/19354/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/57/19354/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/57/19354/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/57/19354/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Group B streptococcus (GBS or Streptococcus agalactiae) is an encapsulated gram-positive coccus that colonizes the gastrointestinal and genital tracts of 15 to 40 percent of pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/1\">",
"     1",
"    </a>",
"    ]. Although GBS colonization usually remains asymptomatic in these women, maternal colonization is the critical determinant of infection in neonates and young infants (less than 90 days of age), in whom GBS is the most common cause of bacterial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Vertical (mother-to-child) transmission primarily occurs when GBS ascends from the vagina to the amniotic fluid after onset of labor or rupture of membranes, but can occur with intact membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the mid-1980s, randomized and controlled clinical trials demonstrated that intrapartum administration of intravenous penicillin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    to GBS carriers protected their newborns from developing early-onset disease (ie, GBS infection at 0 to 6 days of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Based upon this evidence, the Centers for Disease Control and Prevention (CDC) published guidelines for prevention of neonatal GBS disease in 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/4\">",
"     4",
"    </a>",
"    ] and 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/3\">",
"     3",
"    </a>",
"    ]. The key intervention of these guidelines is intrapartum parenteral antibiotic prophylaxis of women whose infants are at high risk of developing early-onset GBS infection because a maternal GBS culture was positive in the weeks before delivery or because of maternal characteristics that increase the risk of early-onset GBS disease in their offspring.",
"   </p>",
"   <p>",
"    The 2010 CDC guidelines for prevention of early-onset GBS disease will be reviewed here. The microbiology, epidemiology, clinical manifestations, and treatment of perinatal and adult GBS infections, and the status of GBS vaccines are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43062?source=see_link\">",
"       \"Group B streptococcal infection in pregnant women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2552?source=see_link\">",
"       \"Management of the infant whose mother has received group B streptococcal chemoprophylaxis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=see_link\">",
"       \"Group B streptococcal infection in neonates and young infants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9621?source=see_link\">",
"       \"Group B streptococcus: Virulence factors and pathogenic mechanisms\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IDENTIFICATION OF COLONIZED GRAVIDAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of women colonized with GBS plays the major role in the prevention of early-onset neonatal disease since GBS infection results from vertical transmission. Colonized women can be identified directly by culture or indirectly by the presence of specific maternal characteristics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2760920\">",
"    <span class=\"h2\">",
"     Culture versus risk factor-based screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first CDC guidelines published in 1996 for use of intrapartum chemoprophylaxis to prevent early-onset GBS infant disease allowed either culture-based or risk-based strategies. The culture-based approach involved performing routine antepartum GBS cultures on all pregnant women, with a few exceptions for women at very high risk of having an infected infant; all colonized women received intrapartum antibiotic prophylaxis. The risk factor-based approach administered intrapartum antibiotic prophylaxis to women with intrapartum risk factors for infant infection (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk factor-based approach'",
"    </a>",
"    below). Although randomized trials directly comparing these two strategies had not been performed at the time these guidelines were written, the bulk of evidence supported culture-based screening followed by intrapartum chemoprophylaxis of women with positive results since the majority of cases of early-onset disease occur in infants of women who have no identifiable risk factors or in whom risk factors are not identified in time to provide effective chemoprophylaxis.",
"   </p>",
"   <p>",
"    The value of routine cultures, rather than assessment of risk factors, was best demonstrated in a retrospective cohort study of deliveries in the United States from 1998 to 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/9\">",
"     9",
"    </a>",
"    ]. Performing lower vaginal and rectal screening cultures at 35 to 37 weeks of gestation and administering antibiotic prophylaxis to GBS carriers was associated with fewer cases of early-onset GBS disease in neonates than prophylaxis based upon the presence of one or more maternal risk factors (adjusted RR 0.46, 95% CI 0.36-0.60). In fact, almost one in five culture-positive women did not have maternal risk factors for early-onset neonatal infection and would not have received intrapartum antibiotic prophylaxis. Based primarily on this study, but also on results from other controlled studies, major organizations in the United States, including the CDC, American College of Obstetricians and Gynecologists, and American Academy of Pediatrics, have recommended screening cultures over risk-based screening for GBS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/3,10\">",
"     3,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4902919\">",
"    <span class=\"h2\">",
"     Culture-based approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC recommends GBS rectovaginal screening cultures for",
"    <strong>",
"     all pregnant women at",
"    </strong>",
"    &nbsp;",
"    <strong>",
"     35 to 37 weeks of gestation",
"    </strong>",
"    , with the following two exceptions: (1) women with GBS bacteriuria (&ge;10",
"    <sup>",
"     4",
"    </sup>",
"    colonies in pure culture or mixed with a second microorganism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/3\">",
"     3",
"    </a>",
"    ]) during the current pregnancy and (2) women who previously gave birth to an infant with invasive GBS disease (see",
"    <a class=\"local\" href=\"#H4903354\">",
"     'Exceptions'",
"    </a>",
"    below). Cultures are performed near term because many women have transient or intermittent disease, thus GBS colonization status in early pregnancy may not be predictive of status late in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/5,11,12\">",
"     5,11,12",
"    </a>",
"    ]. Cultures are performed at 35 to 37 weeks because the results will be available before most women go into labor and are reasonably predictive of GBS status for about five weeks. The negative predictive value of GBS cultures performed &le;5 weeks before delivery is 95 to 98 percent, but declines after five weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4903354\">",
"    <span class=\"h3\">",
"     Exceptions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with GBS bacteriuria anytime in pregnancy should routinely receive prophylactic intrapartum antibiotics; therefore, they can be excluded from culture-based screening. The rationale for this recommendation is that GBS bacteriuria is a marker of heavy vaginal and rectal colonization (the source of GBS bacteriuria in these women), oral treatment of bacteriuria during pregnancy does not achieve long-term eradication of anogenital colonization, and the neonates of women with GBS bacteriuria are at higher risk for early-onset GBS disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/11,13-15\">",
"     11,13-15",
"    </a>",
"    ]. There is expert consensus that symptomatic or asymptomatic women with GBS bacteriuria &ge;10",
"    <sup>",
"     5",
"    </sup>",
"    <span class=\"nowrap\">",
"     cfu/mL",
"    </span>",
"    during pregnancy should be treated according to current standards for treating bacteriuria during pregnancy. The utility of treating GBS bacteriuria at colony counts &lt;10",
"    <sup>",
"     5",
"     <span class=\"nowrap\">",
"     </span>",
"    </sup>",
"    cfu/mL",
"    is uncertain; some favor treatment to prevent urinary tract and other sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/16\">",
"     16",
"    </a>",
"    ], while others do not treat patients with low levels of bacteriuria [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43062?source=see_link\">",
"     \"Group B streptococcal infection in pregnant women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43657?source=see_link\">",
"     \"Urinary tract infections and asymptomatic bacteriuria in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is also good evidence that previous delivery of an infant with early-onset GBS disease is associated with a higher risk of early-onset disease in subsequent deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/9,18-20\">",
"     9,18-20",
"    </a>",
"    ]. For this reason, women with this history should routinely receive prophylactic intrapartum antibiotics, and therefore can be excluded from culture-based screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4902926\">",
"    <span class=\"h2\">",
"     Performance of GBS cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Swabs for culture should be obtained, ideally before digital examination or use of lubricants, from both the lower vagina (vaginal introitus) and rectum (insert swab through the anal sphincter) to achieve maximum sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Either two swabs (one for each site) or a single swab can be used; one swab is more cost efficient. The swabs may be obtained by the patient or a healthcare provider as studies have shown equivalent sensitivity. A speculum should not be used to obtain the vaginal swab specimen. Sites other than the vagina and rectum need not be sampled as they are less sensitive for detection of GBS, and add to the cost.",
"   </p>",
"   <p>",
"    Both swabs, or a single swab of each site, should be placed promptly into non-nutrient transport media (eg, Amies or Stuart's without charcoal) and transported at room temperature (in temperate climates) or refrigerated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/24\">",
"     24",
"    </a>",
"    ]. The swab or swabs are then transferred to an enriched selective broth medium at a laboratory experienced in the isolation of GBS, incubated overnight at 37&ordm;C, and subcultured onto blood agar plates (",
"    <a class=\"graphic graphic_algorithm graphicRef57194 \" href=\"UTD.htm?24/50/25391\">",
"     algorithm 1",
"    </a>",
"    ). Selective media is used to avoid overgrowth of other organisms that may mask GBS growth [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/3\">",
"     3",
"    </a>",
"    ]. The CDC guidelines include detailed steps for isolation and proper identification of the organism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Susceptibility testing is not necessary in most cases because GBS isolates with confirmed resistance to penicillin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    have not been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/25\">",
"     25",
"    </a>",
"    ]. In patients with positive GBS cultures who have a serious allergy to penicillin (history of anaphylaxis, angioedema, respiratory distress, or urticaria), testing for sensitivity to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    should be performed if one of these antibiotics is used for intrapartum antibiotic prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Patients with penicillin allergy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4902953\">",
"    <span class=\"h3\">",
"     Incidental findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some laboratories report nonGBS streptococcal organisms identified during GBS screening cultures.&nbsp;In the only available study, group A Streptococcus (GAS) was present in 0.03 percent of rectovaginal cultures from pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/26\">",
"     26",
"    </a>",
"    ]. Reporting GAS colonization identified during GBS screening should be discouraged because the maternal-fetal-neonatal attack rate of GAS in this setting is unknown (described in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/27\">",
"     27",
"    </a>",
"    ]), opinions about management of these pregnancies vary widely among infectious disease experts, and few guidelines are available [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4902960\">",
"    <span class=\"h3\">",
"     Rapid diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening cultures require 24 to 48 hours to become positive, thus cultures are not useful when obtained in the initial management of patients who present in labor. As will be discussed below, antibiotic prophylaxis is recommended for pregnant women whose culture status is unknown if they have one or more intrapartum risk factor for early-onset infant disease (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Indications for antibiotic prophylaxis'",
"    </a>",
"    below). If a sensitive and specific rapid diagnostic test were available, then GBS testing at the time of hospital admission and limiting intrapartum antibiotic prophylaxis to women with positive test results would be feasible.",
"   </p>",
"   <p>",
"    Rapid detection, polymerase chain reaction (PCR)-based methods perform much better than other antigen-based detection kits. A systematic review of studies using rapid detection tests compared the accuracy of six different tests (PCR, optical immunoassay [OIA], DNA hybridization, enzyme immunoassay, latex agglutination, and Islam starch medium test) to culture for identifying GBS colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/29\">",
"     29",
"    </a>",
"    ]. The methodologic quality of the studies was generally poor. The tests that performed best were real-time PCR (median sensitivity 96 percent, median specificity 98 percent) and OIA (median sensitivity 48 percent, median specificity 97 percent). Real-time PCR took 40 minutes to complete, whereas the OIA took 30 minutes, a difference that is not usually clinically important. Newer generation rapid detection tests with very good sensitivity and specificity, as well as improved ease of use, are becoming commercially available [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In settings in which nucleic acid amplification tests (NAAT) such as PCR for GBS are available, obstetric providers can choose to perform intrapartum testing of vaginal-rectal samples. NAAT testing does not replace culture-based screening during pregnancy, is optional, and is not available in all settings. This test is an option for women at term with unknown GBS colonization status and no intrapartum risk factors for GBS colonization at the time of testing (risk factors = temperature &ge;100.4&ordm;F [&ge;38.0&ordm;C] or rupture of amniotic membranes &ge;18 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/3\">",
"     3",
"    </a>",
"    ]. Women with no risk factors at admission who test positive for GBS should receive intrapartum antibiotic prophylaxis. Women with no risk factors initially but who subsequently develop fever or prolonged rupture of membranes should receive intrapartum antibiotic prophylaxis regardless of the intrapartum testing results. Women who are preterm or who have intrapartum risk factors for GBS colonization at admission should not undergo NAAT; these women should receive intrapartum prophylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factor-based approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of certain characteristics is an indirect means of identifying women whose infants are at increased risk of developing early-onset disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/4\">",
"     4",
"    </a>",
"    ]. These risk factors can be used instead of cultures to identify women who should receive antibiotic prophylaxis in labor to reduce the risk of having an affected infant [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/31-36\">",
"     31-36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intrapartum fever &ge;100.4&ordm;F [&ge;38&ordm;C]",
"     </li>",
"     <li>",
"      Delivery before",
"      <span class=\"nowrap\">",
"       37",
"       <sup>",
"        0/7ths",
"       </sup>",
"      </span>",
"      weeks of gestation",
"     </li>",
"     <li>",
"      Rupture of membranes &ge;18 hours",
"     </li>",
"     <li>",
"      Previous delivery of an infant affected by GBS disease",
"     </li>",
"     <li>",
"      GBS bacteriuria (&ge;10",
"      <sup>",
"       4",
"      </sup>",
"      <span class=\"nowrap\">",
"       cfu/mL)",
"      </span>",
"      in the current pregnancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mathematical modeling suggests that these risk factors classify 25 to 30 percent of intrapartum women as at risk of GBS colonization, a prevalence similar to that predicted by a culture-based approach [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. However, a study that compared the risk-based approach to a culture-based approach for identifying women for intrapartum antibiotic prophylaxis found that nearly 50 percent of women who delivered infants with early-onset GBS disease had none of these listed risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of prolonged rupture of membranes does not override a negative GBS culture within the previous five weeks; GBS prophylaxis is not indicted in this setting. Antibiotics would be indicated if the patient develops clinical signs of infection, such as intrapartum fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INTRAPARTUM ANTIBIOTIC PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics are given intrapartum rather than at the time of a positive culture because antibiotic administration remote from delivery does not eradicate GBS colonization at the time of delivery, which is when the infant is at risk of vertical transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. The intravenous route is required to achieve rapid high concentrations both in maternal serum for placental transfer to the fetal systemic circulation and in the amniotic fluid, which is inhaled and swallowed by the fetus.",
"   </p>",
"   <p>",
"    Women with GBS colonization can enter labor spontaneously or be induced; cesarean delivery should be reserved for standard obstetrical indications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Indications for antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrapartum antibiotic prophylaxis is given in the following settings, which can be identified by laboratory testing, obstetrical history, or physical examination and are predictive of an increased risk of early-onset GBS infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/3\">",
"     3",
"    </a>",
"    ]: (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Identification of colonized gravidas'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positive screening culture for GBS from either vagina or rectum [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Positive history of birth of an infant with early-onset GBS disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/18-20\">",
"       18-20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      GBS bacteriuria during the current pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Unknown culture status (culture not performed or result not available)",
"      <strong>",
"       and",
"      </strong>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      intrapartum fever (&ge;100.4&ordm;F, &ge;38&ordm;C)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      preterm labor (&lt;37 weeks of gestation)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      prolonged rupture of membranes (&ge;18 hours) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/37\">",
"       37",
"      </a>",
"      ]",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      intrapartum NAAT positive for GBS",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis for GBS is not indicated",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrapartum antibiotic prophylaxis is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for women with [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a previous pregnancy, a positive GBS rectovaginal culture or GBS bacteriuria and none of the indications for prophylaxis listed above [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Women with a positive GBS culture who undergo planned cesarean delivery (at any gestational age) without labor or rupture of membranes [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/3,42\">",
"       3,42",
"      </a>",
"      ]. Patients planning cesarean delivery should undergo routine vaginal and rectal screening for GBS at 35 to 37 weeks because onset of labor or rupture of membranes may occur before the planned cesarean delivery and either would be an indication for antibiotic prophylaxis.",
"     </li>",
"     <li>",
"      Pregnant women with negative GBS cultures at 35 to 37 weeks of gestation, even if they have one or more of the following intrapartum risk factors: intrapartum fever (&ge;100.4&ordm;F, &ge;38&ordm;C), preterm labor (&lt;37 weeks of gestation), or prolonged rupture of membranes (&ge;18 hours) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/4\">",
"       4",
"      </a>",
"      ]. However, the use of broad-spectrum intrapartum antibiotics for the treatment (not prophylaxis) is indicated for febrile women in labor if they have clinical evidence of chorioamnionitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Antibiotic regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     Penicillin G",
"    </a>",
"    5 million units intravenously initial dose, then 2.5 to 3 million units intravenously every four hours until delivery is recommended for intrapartum antibiotic prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/3\">",
"     3",
"    </a>",
"    ]. GBS isolates with confirmed resistance to penicillin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    have not been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/25\">",
"     25",
"    </a>",
"    ]. Ampicillin 2 g intravenously initial dose, then 1 g intravenously every four hours until delivery can be used, but penicillin is preferred based upon its narrower spectrum of activity, which theoretically reduces the opportunity for development of ampicillin-resistant organisms (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Development of antibiotic resistance'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    GBS is susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , extended-spectrum penicillins, cephalosporins, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , but penicillin G is the most active agent in vitro. Approximately 30 percent of GBS isolates are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and 20 percent are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , and these rates appear to be increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/43-47\">",
"     43-47",
"    </a>",
"    ]. Erythromycin is no longer recommended for prophylaxis, while clindamycin use depends on results of multiple susceptibility tests (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Patients with penicillin allergy'",
"    </a>",
"    below). Most isolates are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral treatment is not recommended, although randomized trials comparing oral versus parenteral therapy have not been performed. In laboring women, absorption from the gastrointestinal tract is not reliable because of delayed transit time and vomiting. The intravenous route is required to achieve rapid high concentrations both in maternal serum for placental transfer to the fetal systemic circulation and in the amniotic fluid, which is inhaled and swallowed by the fetus. Also, the high dose of antibiotics required to rapidly reduce the number of organisms in the genital secretions and amniotic fluid (if colonized) to prevent neonatal infection cannot be tolerated orally. In non-laboring women, prospective studies found that oral therapy did not substantially reduce rectovaginal colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/41,49\">",
"     41,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Patients with penicillin allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient's history suggests a \"low risk\" for anaphylaxis (eg, isolated maculopapular rash without urticaria or pruritus), then",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    2 g initial dose, then 1 g every eight hours until delivery is recommended for intrapartum antibiotic prophylaxis (",
"    <a class=\"graphic graphic_algorithm graphicRef70001 \" href=\"UTD.htm?2/17/2335\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .) This recommendation is based on the ability of cefazolin to reach bactericidal concentrations in the amniotic fluid three hours after an intravenous dose.",
"   </p>",
"   <p>",
"    If the patient's history suggests a \"high risk\" for anaphylaxis (eg, anaphylaxis, angioedema, respiratory distress, urticaria, particularly if these symptoms occurred within 30 minutes of drug administration), then antibiotic susceptibility testing of GBS isolates must be performed to verify susceptibility to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    . If laboratory facilities are adequate, clindamycin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    susceptibility testing is recommended on prenatal GBS isolates from penicillin-allergic women at high risk for anaphylaxis. Resistance to erythromycin is often associated with clindamycin resistance. If an isolate is resistant to erythromycin, it may have inducible resistance to clindamycin, even if it appears susceptible to clindamycin by standard in vitro testing methods. If a GBS isolate is susceptible to clindamycin, resistant to erythromycin, and D-zone testing for inducible resistance is negative (no inducible resistance), then clindamycin 900 mg intravenously every eight hours until delivery can be used for GBS intrapartum prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the GBS isolate is resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    or susceptibility results are not available, then the CDC recommends use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    1 g every 12 hours in patients with normal renal function until delivery of the infant [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/3\">",
"     3",
"    </a>",
"    ]. Recent infectious disease guidelines have advocated weight-based dosing of vancomycin (15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    because a large percentage of American women are obese. Neither clindamycin nor vancomycin has been evaluated for effectiveness in preventing early-onset GBS and their pharmacokinetic profile is not favorable to achieving bactericidal concentrations in the amniotic fluid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/47/15096?source=see_link\">",
"     \"Vancomycin dosing and serum concentration monitoring in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An alternative approach is to perform penicillin skin testing in a woman with a history of penicillin allergy to determine her allergy status [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/50\">",
"     50",
"    </a>",
"    ]. Patients with negative skin tests could then receive intrapartum antibiotic prophylaxis with penicillin. However, patients with negative skin tests should avoid taking a penicillin-based drug until it is administered for intrapartum antibiotic prophylaxis, due to a small potential risk of re-sensitization from a subsequent course. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2008, 76 percent of GBS-positive women who were allergic to penicillin in one large hospital received an appropriate antibiotic compared with 16 percent in 2004 to 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/51\">",
"     51",
"    </a>",
"    ]. The improvement in antibiotic selection was the result of educating providers through lectures, publicizing the CDC guidelines on posters throughout the hospital, and adding a field for &ldquo;PCN allergy&rdquo; to the laboratory ordering systems so that, if filled out properly, the laboratory could be reflexively prompted to perform GBS sensitivity testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4905148\">",
"    <span class=\"h2\">",
"     Timing and duration of prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrapartum antibiotic prophylaxis with penicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    is most effective if administered at least four hours before delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/48,52,53\">",
"     48,52,53",
"    </a>",
"    ]. Although fetal serum penicillin levels with these agents are high within 30 minutes of a maternal intravenous infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/54,55\">",
"     54,55",
"    </a>",
"    ] and maternal vaginal GBS colony counts begin to fall promptly after beginning intravenous antibiotics, the nadir in GBS colony counts in the amniotic and vaginal fluid is not reached until approximately three hours after the first antibiotic dose [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the time of delivery cannot be predicted, prophylaxis is begun at hospital admission for labor or rupture of membranes and continued every four hours until the infant is delivered. Few studies examining the optimum duration of intrapartum antibiotic prophylaxis have been reported, but cases of early-onset neonatal disease are rare if appropriate doses of penicillin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    are given, if four or more hours have passed between the first dose and delivery, and if no maternal infection (eg, chorioamnionitis or bacteremia) is present. In an observational study of 33 GBS carriers with preterm premature rupture of membranes receiving penicillin prophylaxis, daily genital tract cultures for GBS were negative in",
"    <span class=\"nowrap\">",
"     29/33",
"    </span>",
"    patients (88 percent) by day 1, in",
"    <span class=\"nowrap\">",
"     32/33",
"    </span>",
"    patients by day 2, and in all 33 patients by day 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medically necessary procedures should not be delayed in order to provide four hours between antibiotic administration and the procedure.",
"   </p>",
"   <p>",
"    Recolonization can occur after cessation of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     APPROACH TO THREATENED PRETERM DELIVERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4905413\">",
"    <span class=\"h2\">",
"     Preterm labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The colonization status of women admitted with preterm labor or preterm rupture of membranes generally is not known since screening is performed at 35 to 37 weeks of gestation to maximize agreement between antepartum culture results and maternal GBS status at delivery. If colonization status is unknown, GBS cultures are obtained at time of presentation and then antibiotic prophylaxis is administered. If the patient is in true preterm labor, GBS prophylaxis is continued until she delivers. If after a period of observation the patient is not felt to be in true labor, GBS prophylaxis should be discontinued (",
"    <a class=\"graphic graphic_algorithm graphicRef72587 \" href=\"UTD.htm?36/22/37230\">",
"     algorithm 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It takes 48 hours to definitively exclude GBS. If the culture result is negative after 48 hours, no GBS prophylaxis is needed if preterm labor recurs within the next five weeks. Culture results are not predictive of GBS status for more than five weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/12\">",
"     12",
"    </a>",
"    ], so if preterm labor occurs more than five weeks after the negative culture, the approach is the same as that for a woman with unknown colonization status.",
"   </p>",
"   <p>",
"    Women with positive GBS cultures should be given GBS prophylaxis if admitted in preterm labor. If undelivered at 35 to 37 weeks of gestation, a vaginal-rectal culture should be repeated to predict GBS status and guide management if the pregnancy goes to term.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Preterm premature rupture of membranes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with chorioamnionitis typically receive broad-spectrum antibiotic therapy. This therapy should include an agent known to be active against GBS to replace GBS prophylaxis.",
"   </p>",
"   <p>",
"    Women with preterm premature rupture of membranes undergoing expectant management and given antibiotics for latency should receive a regimen that includes prophylaxis for GBS, after GBS cultures have been obtained (",
"    <a class=\"graphic graphic_algorithm graphicRef60841 \" href=\"UTD.htm?40/5/41054\">",
"     algorithm 4",
"    </a>",
"    ). GBS prophylaxis is discontinued if the cultures are negative for GBS. The management of these patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link&amp;anchor=H20#H20\">",
"     \"Preterm premature rupture of membranes\", section on 'Chemoprophylaxis for GBS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal intrapartum GBS chemoprophylaxis has resulted in a significant reduction in early-onset GBS disease (&gt;80 percent of cases) and neonatal death [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/4,58-60\">",
"     4,58-60",
"    </a>",
"    ]. Late-onset GBS disease has remained stable or decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Early-onset GBS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2013 Cochrane review of randomized trials of intrapartum antibiotic treatment of women colonized with GBS found that intrapartum antibiotic prophylaxis significantly reduced the rate of early-onset neonatal GBS infection (OR 0.17, 95% CI 0.04-0.74), and a nonstatistical reduction in neonatal mortality (all cause mortality RR 0.19, 95% CI 0.01-3.92; mortality from early onset GBS RR 0.31, 95% CI 0.01-7.50) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, widespread use of GBS screening and intrapartum antibiotic prophylaxis has resulted in a substantial decrease in early-onset GBS infections (ie, diagnosis of neonatal GBS infection within six days after birth). This was illustrated in a report from the CDC showing that, in 1993, before active efforts at prevention, the incidence of early-onset GBS infection was 1.5 per 1000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/4\">",
"     4",
"    </a>",
"    ]. After publication of the initial recommendations in the 1990s (risk factor-based approach), the incidence of early-onset disease fell to 0.52 per 1000 live births (in 2000). Revision of these recommendations in 2002 (universal screening) was associated with a further drop in incidence to 0.31 cases per 1000 live births (in 2003), a rise to 0.40 cases per 1000 live births in 2006, and then a fall to 0.24 cases per 1000 live births in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/3,59,62\">",
"     3,59,62",
"    </a>",
"    ]. This was mostly due to a significant increase in early-onset disease from 2003 to 2006 among term black infants (from 0.33 to 0.70 cases per 1000 live births).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2502761\">",
"    <span class=\"h3\">",
"     Late-onset GBS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the US, the incidence of late-onset GBS infection (7 to 89 days after birth) has remained stable at an average 0.35",
"    <span class=\"nowrap\">",
"     cases/1000",
"    </span>",
"    live births [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/62\">",
"     62",
"    </a>",
"    ]. The incidence of late-onset GBS infection in Europe appears to be similar to or slightly lower than that in the US, but is less well-defined because most European studies have not performed population-based active surveillance of culture-confirmed invasive infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Missed cases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some women colonized at delivery are not identified, despite screening. About 4 percent of women who test negative at 35 to 37 weeks have a false negative result, and about 60 percent of early-onset GBS occurs in these women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/12,63-65\">",
"     12,63-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 25 neonates with early-onset GBS, maternal GBS cultures at 35 to 37 weeks of gestation were presumably falsely negative in 16 (64 percent); the mothers in 19 of these 25 pregnancies had one or more risk factors for early-onset GBS infection (delivery at &lt;37 weeks, intrapartum fever &gt;100.4&ordm;F, clinical chorioamnionitis, or GBS colonization) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another retrospective review included 254 cases of early-onset GBS among 7691 live births from a multi-state GBS surveillance system [",
"      <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/64\">",
"       64",
"      </a>",
"      ]. About 75 percent of GBS cases",
"      <span class=\"nowrap\">",
"       (189/254)",
"      </span>",
"      occurred in term infants, but only about one-fifth of these cases",
"      <span class=\"nowrap\">",
"       (37/189)",
"      </span>",
"      occurred in women whose screen results were positive; 116 cases (61.4 percent) occurred in women whose screen results were negative, 34 cases (13.4 percent) were attributed to missed screening, and two cases occurred in women whose screen results were not known.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The methods used for processing screening cultures in these studies were not described, and may have affected the results. These findings suggest that more sensitive methods of detection would be useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Development of antibiotic resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a theoretical possibility that extensive use of intrapartum prophylaxis could result in increased antibiotic resistance among GBS isolates",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an increased incidence of infections due to other pathogens. Thus far, no consistent trends have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/66-75\">",
"     66-75",
"    </a>",
"    ]. A population-based GBS surveillance program in 10 states tested 4882 GBS isolates and found that 100 percent were sensitive to penicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , but 32 percent were resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and 15 percent were resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/76\">",
"     76",
"    </a>",
"    ]. Susceptibility to first generation cephalosporins was not assessed; however, a similar population-based surveillance study reported all GBS isolates were sensitive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exposure to broad-spectrum intrapartum antibiotic prophylaxis has been associated with an increased risk of late-onset serious bacterial infections and infection with resistant organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/71,78,79\">",
"     71,78,79",
"    </a>",
"    ]. These findings support the recommendation to use penicillin as the preferred agent for GBS prophylaxis, rather than broader spectrum antibiotics, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     GBS PROPHYLAXIS FOR OBSTETRICAL PROCEDURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95981696\">",
"    <span class=\"h2\">",
"     Antepartum procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no high quality data about the usefulness of antibiotic prophylaxis of antepartum obstetrical procedures in women colonized with GBS or in those in whom GBS status is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/4\">",
"     4",
"    </a>",
"    ]. Such procedures include vaginal examination, placement of devices for cervical ripening, and membrane",
"    <span class=\"nowrap\">",
"     stripping/sweeping.",
"    </span>",
"    In the absence of such data, we suggest not administering prophylactic antibiotics.",
"   </p>",
"   <p>",
"    Low quality indirect support for avoiding chemoprophylaxis was provided by a meta-analysis of 19 trials of membrane stripping for induction of labor in women of undetermined GBS status [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/80\">",
"     80",
"    </a>",
"    ]. The prevalence of neonatal infection among neonates exposed and unexposed to this procedure was similar.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95981703\">",
"    <span class=\"h2\">",
"     Intrapartum procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is also no evidence that intrapartum vaginal examinations and other clinically indicated invasive procedures increase the risk of early-onset GBS infection in infants of women who are known to be colonized [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/81\">",
"     81",
"    </a>",
"    ]. Positive GBS carrier status is not a contraindication to amniotomy, if clinically indicated. Ideally, amniotomy and other invasive procedures are performed at least four hours after intrapartum antibiotic prophylaxis has been initiated; however,",
"    <span class=\"nowrap\">",
"     medically/obstetrically",
"    </span>",
"    indicated procedures should not be delayed to achieve an optimal antibiotic concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     NEWBORNS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3800229\">",
"    <span class=\"h2\">",
"     Preventive strategies after birth",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of prevention strategies targeting newborns, rather than maternal colonization, is controversial. Large observational studies have suggested that administration of intramuscular penicillin to the newborn immediately after delivery may reduce early-onset GBS disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. However, a nonblinded randomized trial involving 1187 infants failed to identify a benefit in outcome of GBS disease or neonatal mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The discrepancy between the results of the observational studies and the randomized trial may be explained by methodologic issues [",
"    <a class=\"abstract\" href=\"UTD.htm?18/57/19354/abstract/85\">",
"     85",
"    </a>",
"    ]. The randomized trial may not have included sufficient numbers of patients to detect a difference in outcome between treated and control infants. In addition, the participants in the randomized trial were preterm low birth-weight infants who were transferred to a neonatal intensive care unit. Twenty of 24 infected babies became symptomatic within the first hour of life, suggesting that infection may have been present at the time of delivery. Finally, there were differences in general management that may have contributed to the discrepant findings. Unless high quality evidence becomes available, the standard for prevention of early-onset GBS disease is maternal rather than newborn chemoprophylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3800168\">",
"    <span class=\"h2\">",
"     Management of newborns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of newborns is discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2552?source=see_link\">",
"       \"Management of the infant whose mother has received group B streptococcal chemoprophylaxis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=see_link\">",
"       \"Group B streptococcal infection in neonates and young infants\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34535601\">",
"    <span class=\"h1\">",
"     GUIDELINES FROM NATIONAL ORGANIZATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.rcog.org.uk/womens-health/clinical-guidance/prevention-early-onset-neonatal-group-b-streptococcal-disease-green-\">",
"       Royal College of Obstetricians and Gynecologists",
"      </a>",
"      . The Prevention of Early-onset neonatal Group B Streptococcal Disease. Green-top guideline No. 36 July 2012.",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.sogc.org/guidelines/public/149E-CPG-September2004.pdf\">",
"       Society of Obstetricians and Gynaecologists of Canada",
"      </a>",
"      . The Prevention of Early-Onset Neonatal Group B Streptococcal Disease. September 2004.",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.ranzcog.edu.au/the-ranzcog/policies-and-guidelines/college-statements/414--screening-and-treatment-for-group-b-streptococcus-in-pregnancy-c-obs-19.html\">",
"       Royal Australian and New Zealand College of Obstetricians and Gynaecologists",
"      </a>",
"      . Screening and Treatment for Group B Streptococcus in Pregnancy. July 2011.",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.cdc.gov/groupbstrep/guidelines/guidelines.html\">",
"       Centers for Disease Control and Prevention",
"      </a>",
"      . 2010 Guidelines for the Prevention of Perinatal Group B Streptococcal Disease (endorsed by the American Academy of Family Physicians, American Academy of Pediatrics, American College of Obstetricians and Gynecologists, American College of Nurse-Midwives).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/42/42657?source=see_link\">",
"       \"Patient information: Group B streptococcal disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11248?source=see_link\">",
"       \"Patient information: Group B streptococcus and pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal Group B streptococcal (GBS) colonization occurs in 10 to 40 percent of women and is the critical determinant of early-onset GBS infection in neonates less than 7 days of age. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend universal screening of pregnant women to identify those at risk for having a newborn with early-onset GBS disease (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Colonized women can transmit GBS to offspring, resulting in early-onset disease in neonates, and some of these cases will be missed if a selective risk factor based approach is taken. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Identification of colonized gravidas'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend obtaining GBS cultures at 35 to 37 weeks of gestation, rather than a risk factor-based approach. Women with GBS bacteriuria anytime in pregnancy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) or an infant with early-onset GBS infection in a previous pregnancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) should routinely receive prophylactic intrapartum antibiotics; therefore, they can be excluded from culture-based screening. (See",
"      <a class=\"local\" href=\"#H4902919\">",
"       'Culture-based approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4903354\">",
"       'Exceptions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Swabs for GBS culture should be obtained from both the lower vagina (not cervix) and rectum (not the anal orifice) to achieve maximum sensitivity; these should be placed in transport media, sent to the laboratory and inoculated into selective media for incubation and further processing. (See",
"      <a class=\"local\" href=\"#H4902926\">",
"       'Performance of GBS cultures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with positive GBS cultures from either the vagina or rectum, we recommend intrapartum antibiotic prophylaxis at the onset of labor, with administration until delivery (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Intrapartum antibiotic prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with positive GBS vaginal-rectal cultures undergoing a planned cesarean delivery in the absence of labor or rupture of membranes, we recommend",
"      <strong>",
"       not",
"      </strong>",
"      administering intrapartum antibiotic prophylaxis, given the low risk of early-onset disease (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Intrapartum antibiotic prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with intrapartum fever (&ge;100.4&ordm;F, &ge;38&ordm;C) whose culture status is unknown (culture not performed or result not available) should receive intrapartum antibiotic treatment (not prophylaxis) that includes an agent active against GBS. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Intrapartum antibiotic prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The colonization status of women who present with threatened preterm delivery generally is not known. In these women, we suggest obtaining a GBS rectovaginal culture and giving antibiotic prophylaxis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Continuation of therapy is then guided by culture results and uterine activity. Antibiotic therapy is continued until delivery or until the threat of imminent preterm delivery has passed. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Approach to threatened preterm delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women in labor with unknown culture status, we recommend intrapartum antibiotic prophylaxis if the gestational age is less than 37 weeks or the duration of membrane rupture is &ge;18 hours (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Maternal temperature &ge;100.4&ordm; F (&ge;38.0&ordm;C) is suggestive of infection and should be treated with antibiotics that provide activity against GBS. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Intrapartum antibiotic prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intrapartum antibiotic prophylaxis is most effective if penicillin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      are administered at least four hours before delivery. (See",
"      <a class=\"local\" href=\"#H4905148\">",
"       'Timing and duration of prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women without penicillin allergy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      is the preferred drug for prophylaxis, given its low cost, low incidence of side effects, and uniform GBS susceptibility. The Centers for Disease Control recommend a dose of 5 million units intravenously initially, then 2.5 to 3 million units intravenously every four hours until delivery.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       Ampicillin",
"      </a>",
"      2 g intravenously initial dose then 1 g every four hours until delivery is an acceptable alternative. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Antibiotic regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with a non-serious penicillin allergy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      is recommended in place of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Patients with penicillin allergy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with penicillin allergy at risk for anaphylaxis,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      is recommended",
"      <strong>",
"       if",
"      </strong>",
"      susceptibility testing has been performed and sensitivity to clindamycin is documented. If the GBS isolate is resistant to clindamycin or susceptibility results are not available, then",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (1 g every 12 hours) should be given. Neither clindamycin nor vancomycin has been evaluated for effectiveness in preventing early-onset GBS infant disease. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Patients with penicillin allergy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antepartum antibiotic treatment of GBS colonization remote from delivery does not reduce the incidence of GBS colonization at the time of delivery, and should be avoided. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Intrapartum antibiotic prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with unknown culture status at term and no risk factors for early-onset GBS disease who test positive for GBS with intrapartum NAAT should receive intrapartum antibiotic prophylaxis. (See",
"      <a class=\"local\" href=\"#H4902960\">",
"       'Rapid diagnostic tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/1\">",
"      Regan JA, Klebanoff MA, Nugent RP. The epidemiology of group B streptococcal colonization in pregnancy. Vaginal Infections and Prematurity Study Group. Obstet Gynecol 1991; 77:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/2\">",
"      Baker CJ, Barrett FF. Transmission of group B streptococci among parturient women and their neonates. J Pediatr 1973; 83:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/3\">",
"      Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/4\">",
"      Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/5\">",
"      Boyer KM, Gadzala CA, Kelly PD, et al. Selective intrapartum chemoprophylaxis of neonatal group B streptococcal early-onset disease. II. Predictive value of prenatal cultures. J Infect Dis 1983; 148:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/6\">",
"      Boyer KM, Gotoff SP. Prevention of early-onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis. N Engl J Med 1986; 314:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/7\">",
"      Easmon CS, Hastings MJ, Deeley J, et al. The effect of intrapartum chemoprophylaxis on the vertical transmission of group B streptococci. Br J Obstet Gynaecol 1983; 90:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/8\">",
"      Boyer KM, Gadzala CA, Kelly PD, Gotoff SP. Selective intrapartum chemoprophylaxis of neonatal group B streptococcal early-onset disease. III. Interruption of mother-to-infant transmission. J Infect Dis 1983; 148:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/9\">",
"      Schrag SJ, Zell ER, Lynfield R, et al. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med 2002; 347:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/10\">",
"      American College of Obstetricians and Gynecologists Committee on Obstetric Practice. ACOG Committee Opinion No. 485: Prevention of early-onset group B streptococcal disease in newborns. Obstet Gynecol 2011; 117:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/11\">",
"      Regan JA, Klebanoff MA, Nugent RP, et al. Colonization with group B streptococci in pregnancy and adverse outcome. VIP Study Group. Am J Obstet Gynecol 1996; 174:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/12\">",
"      Yancey MK, Schuchat A, Brown LK, et al. The accuracy of late antenatal screening cultures in predicting genital group B streptococcal colonization at delivery. Obstet Gynecol 1996; 88:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/13\">",
"      Persson K, Christensen KK, Christensen P, et al. Asymptomatic bacteriuria during pregnancy with special reference to group B streptococci. Scand J Infect Dis 1985; 17:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/14\">",
"      Wood EG, Dillon HC Jr. A prospective study of group B streptococcal bacteriuria in pregnancy. Am J Obstet Gynecol 1981; 140:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/15\">",
"      Yancey MK, Duff P, Kubilis P, et al. Risk factors for neonatal sepsis. Obstet Gynecol 1996; 87:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/16\">",
"      Aungst M, King J, Steele A, Gordon M. Low colony counts of asymptomatic group B streptococcus bacteriuria: a survey of practice patterns. Am J Perinatol 2004; 21:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/17\">",
"      Allen VM, Yudin MH, Bouchard C, et al. Management of group B streptococcal bacteriuria in pregnancy. J Obstet Gynaecol Can 2012; 34:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/18\">",
"      Christensen KK, Dahlander K, Lind&eacute;n V, et al. Obstetrical care in future pregnancies after fetal loss in group B streptococcal septicemia. A prevention program based on bacteriological and immunological follow-up. Eur J Obstet Gynecol Reprod Biol 1981; 12:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/19\">",
"      Faxelius G, Bremme K, Kvist-Christensen K, et al. Neonatal septicemia due to group B streptococci--perinatal risk factors and outcome of subsequent pregnancies. J Perinat Med 1988; 16:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/20\">",
"      Carstensen H, Christensen KK, Grennert L, et al. Early-onset neonatal group B streptococcal septicaemia in siblings. J Infect 1988; 17:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/21\">",
"      Badri MS, Zawaneh S, Cruz AC, et al. Rectal colonization with group B streptococcus: relation to vaginal colonization of pregnant women. J Infect Dis 1977; 135:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/22\">",
"      Knudtson EJ, Lorenz LB, Skaggs VJ, et al. The effect of digital cervical examination on group B streptococcal culture. Am J Obstet Gynecol 2010; 202:58.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/23\">",
"      Schwope OI, Chen KT, Mehta I, et al. The effect of a chlorhexidine-based surgical lubricant during pelvic examination on the detection of group B Streptococcus. Am J Obstet Gynecol 2010; 202:276.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/24\">",
"      Larsen JW, Sever JL. Group B Streptococcus and pregnancy: a review. Am J Obstet Gynecol 2008; 198:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/25\">",
"      Andrews JI, Diekema DJ, Hunter SK, et al. Group B streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere. Am J Obstet Gynecol 2000; 183:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/26\">",
"      Mead PB, Winn WC. Vaginal-rectal colonization with group A streptococci in late pregnancy. Infect Dis Obstet Gynecol 2000; 8:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/27\">",
"      Stefonek KR, Maerz LL, Nielsen MP, et al. Group A streptococcal puerperal sepsis preceded by positive surveillance cultures. Obstet Gynecol 2001; 98:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/28\">",
"      Steer JA, Lamagni T, Healy B, et al. Guidelines for prevention and control of group A streptococcal infection in acute healthcare and maternity settings in the UK. J Infect 2012; 64:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/29\">",
"      Honest H, Sharma S, Khan KS. Rapid tests for group B Streptococcus colonization in laboring women: a systematic review. Pediatrics 2006; 117:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/30\">",
"      El Helali N, Nguyen JC, Ly A, et al. Diagnostic accuracy of a rapid real-time polymerase chain reaction assay for universal intrapartum group B streptococcus screening. Clin Infect Dis 2009; 49:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/31\">",
"      Adair CE, Kowalsky L, Quon H, et al. Risk factors for early-onset group B streptococcal disease in neonates: a population-based case-control study. CMAJ 2003; 169:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/32\">",
"      Oddie S, Embleton ND. Risk factors for early onset neonatal group B streptococcal sepsis: case-control study. BMJ 2002; 325:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/33\">",
"      Zaleznik DF, Rench MA, Hillier S, et al. Invasive disease due to group B Streptococcus in pregnant women and neonates from diverse population groups. Clin Infect Dis 2000; 30:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/34\">",
"      Schuchat A, Zywicki SS, Dinsmoor MJ, et al. Risk factors and opportunities for prevention of early-onset neonatal sepsis: a multicenter case-control study. Pediatrics 2000; 105:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/35\">",
"      Schuchat A, Deaver-Robinson K, Plikaytis BD, et al. Multistate case-control study of maternal risk factors for neonatal group B streptococcal disease. The Active Surveillance Study Group. Pediatr Infect Dis J 1994; 13:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/36\">",
"      Boyer KM, Gadzala CA, Burd LI, et al. Selective intrapartum chemoprophylaxis of neonatal group B streptococcal early-onset disease. I. Epidemiologic rationale. J Infect Dis 1983; 148:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/37\">",
"      Boyer KM, Gotoff SP. Strategies for chemoprophylaxis of GBS early-onset infections. Antibiot Chemother 1985; 35:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/38\">",
"      Rouse DJ, Goldenberg RL, Cliver SP, et al. Strategies for the prevention of early-onset neonatal group B streptococcal sepsis: a decision analysis. Obstet Gynecol 1994; 83:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/39\">",
"      Centers for Disease Control and Prevention (CDC). Laboratory practices for prenatal Group B streptococcal screening and reporting--Connecticut, Georgia, and Minnesota, 1997-1998. MMWR Morb Mortal Wkly Rep 1999; 48:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/40\">",
"      Klebanoff MA, Regan JA, Rao AV, et al. Outcome of the Vaginal Infections and Prematurity Study: results of a clinical trial of erythromycin among pregnant women colonized with group B streptococci. Am J Obstet Gynecol 1995; 172:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/41\">",
"      Gardner SE, Yow MD, Leeds LJ, et al. Failure of penicillin to eradicate group B streptococcal colonization in the pregnant woman. A couple study. Am J Obstet Gynecol 1979; 135:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/42\">",
"      Ramus, RM, McIntire, DD, Wendel, GD, Jr. Antibiotic chemoprophylaxis for group B strep is not necessary with elective cesarean section at term [Abstract]. Am J Obstet Gynecol 1999; 180:S85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/43\">",
"      Pearlman MD, Pierson CL, Faix RG. Frequent resistance of clinical group B streptococci isolates to clindamycin and erythromycin. Obstet Gynecol 1998; 92:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/44\">",
"      Biedenbach DJ, Stephen JM, Jones RN. Antimicrobial susceptibility profile among beta-haemolytic Streptococcus spp. collected in the SENTRY Antimicrobial Surveillance Program--North America, 2001. Diagn Microbiol Infect Dis 2003; 46:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/45\">",
"      Manning SD, Foxman B, Pierson CL, et al. Correlates of antibiotic-resistant group B streptococcus isolated from pregnant women. Obstet Gynecol 2003; 101:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/46\">",
"      Manning SD, Pearlman MD, Tallman P, et al. Frequency of antibiotic resistance among group B Streptococcus isolated from healthy college students. Clin Infect Dis 2001; 33:E137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/47\">",
"      de Azavedo JC, McGavin M, Duncan C, et al. Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada. Antimicrob Agents Chemother 2001; 45:3504.",
"     </a>",
"    </li>",
"    <li>",
"     Edwards MS, Nizet V, Baker CJ. Group B Streptococcal Infections. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington JS, Klein JO, Wilson CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.419.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/49\">",
"      Baecher L, Grobman W. Prenatal antibiotic treatment does not decrease group B streptococcus colonization at delivery. Int J Gynaecol Obstet 2008; 101:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/50\">",
"      Macy E. Penicillin skin testing in pregnant women with a history of penicillin allergy and group B streptococcus colonization. Ann Allergy Asthma Immunol 2006; 97:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/51\">",
"      Critchfield AS, Lievense SP, Raker CA, Matteson KA. Group B Streptococcus prophylaxis in patients who report a penicillin allergy: a follow-up study. Am J Obstet Gynecol 2011; 204:150.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/52\">",
"      de Cueto M, Sanchez MJ, Sampedro A, et al. Timing of intrapartum ampicillin and prevention of vertical transmission of group B streptococcus. Obstet Gynecol 1998; 91:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/53\">",
"      Fairlie T, Zell, ER, Schrag S. Effectiveness of Intrapartum Antibiotic Prophylaxis for Prevention of Early-Onset Group B Streptococcal Disease. Obstet Gynecol 2013; 121:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/54\">",
"      Barber EL, Zhao G, Buhimschi IA, Illuzzi JL. Duration of intrapartum prophylaxis and concentration of penicillin G in fetal serum at delivery. Obstet Gynecol 2008; 112:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/55\">",
"      Pacifici GM. Placental transfer of antibiotics administered to the mother: a review. Int J Clin Pharmacol Ther 2006; 44:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/56\">",
"      McNanley AR, Glantz JC, Hardy DJ, Vicino D. The effect of intrapartum penicillin on vaginal group B streptococcus colony counts. Am J Obstet Gynecol 2007; 197:583.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/57\">",
"      Alvarez JR, Williams SF, Ganesh VL, Apuzzio JJ. Duration of antimicrobial prophylaxis for group B streptococcus in patients with preterm premature rupture of membranes who are not in labor. Am J Obstet Gynecol 2007; 197:390.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/58\">",
"      Ohlsson A, Shah VS. Intrapartum antibiotics for known maternal Group B streptococcal colonization. Cochrane Database Syst Rev 2013; 1:CD007467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/59\">",
"      Centers for Disease Control and Prevention (CDC). Trends in perinatal group B streptococcal disease - United States, 2000-2006. MMWR Morb Mortal Wkly Rep 2009; 58:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/60\">",
"      Edmond KM, Kortsalioudaki C, Scott S, et al. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 2012; 379:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/61\">",
"      Didier C, Streicher MP, Chognot D, et al. Late-onset neonatal infections: incidences and pathogens in the era of antenatal antibiotics. Eur J Pediatr 2012; 171:681.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention (2008) Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2007. file://www.cdc.gov/abcs/reports-findings/survreports/gbs07.pdf (Accessed on March 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/63\">",
"      Puopolo KM, Madoff LC, Eichenwald EC. Early-onset group B streptococcal disease in the era of maternal screening. Pediatrics 2005; 115:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/64\">",
"      Van Dyke MK, Phares CR, Lynfield R, et al. Evaluation of universal antenatal screening for group B streptococcus. N Engl J Med 2009; 360:2626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/65\">",
"      Lin FY, Weisman LE, Azimi P, et al. Assessment of intrapartum antibiotic prophylaxis for the prevention of early-onset group B Streptococcal disease. Pediatr Infect Dis J 2011; 30:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/66\">",
"      Sutkin G, Krohn MA, Heine RP, Sweet RL. Antibiotic prophylaxis and non-group B streptococcal neonatal sepsis. Obstet Gynecol 2005; 105:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/67\">",
"      Chen KT, Puopolo KM, Eichenwald EC, et al. No increase in rates of early-onset neonatal sepsis by antibiotic-resistant group B Streptococcus in the era of intrapartum antibiotic prophylaxis. Am J Obstet Gynecol 2005; 192:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/68\">",
"      Towers CV, Carr MH, Padilla G, Asrat T. Potential consequences of widespread antepartal use of ampicillin. Am J Obstet Gynecol 1998; 179:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/69\">",
"      Towers CV, Briggs GG. Antepartum use of antibiotics and early-onset neonatal sepsis: the next 4 years. Am J Obstet Gynecol 2002; 187:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/70\">",
"      Mercer BM, Carr TL, Beazley DD, et al. Antibiotic use in pregnancy and drug-resistant infant sepsis. Am J Obstet Gynecol 1999; 181:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/71\">",
"      Glasgow TS, Young PC, Wallin J, et al. Association of intrapartum antibiotic exposure and late-onset serious bacterial infections in infants. Pediatrics 2005; 116:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/72\">",
"      Rentz AC, Samore MH, Stoddard GJ, et al. Risk factors associated with ampicillin-resistant infection in newborns in the era of group B streptococcal prophylaxis. Arch Pediatr Adolesc Med 2004; 158:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/73\">",
"      Sinha A, Yokoe D, Platt R. Intrapartum antibiotics and neonatal invasive infections caused by organisms other than group B streptococcus. J Pediatr 2003; 142:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/74\">",
"      Schrag SJ, Hadler JL, Arnold KE, et al. Risk factors for invasive, early-onset Escherichia coli infections in the era of widespread intrapartum antibiotic use. Pediatrics 2006; 118:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/75\">",
"      Puopolo KM, Eichenwald EC. No change in the incidence of ampicillin-resistant, neonatal, early-onset sepsis over 18 years. Pediatrics 2010; 125:e1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/76\">",
"      Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008; 299:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/77\">",
"      Castor ML, Whitney CG, Como-Sabetti K, et al. Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Obstet Gynecol 2008; 2008:727505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/78\">",
"      Bizzarro MJ, Dembry LM, Baltimore RS, Gallagher PG. Changing patterns in neonatal Escherichia coli sepsis and ampicillin resistance in the era of intrapartum antibiotic prophylaxis. Pediatrics 2008; 121:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/79\">",
"      Ecker KL, Donohue PK, Kim KS, et al. The impact of group B streptococcus prophylaxis on late-onset neonatal infections. J Perinatol 2013; 33:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/80\">",
"      Boulvain M, Stan C, Irion O. Membrane sweeping for induction of labour. Cochrane Database Syst Rev 2005; :CD000451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/81\">",
"      Gibbs RS, Schrag S, Schuchat A. Perinatal infections due to group B streptococci. Obstet Gynecol 2004; 104:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/82\">",
"      Siegel JD, McCracken GH Jr, Threlkeld N, et al. Single-dose penicillin prophylaxis of neonatal group-B-streptococcal disease. Lancet 1982; 1:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/83\">",
"      Patel DM, Rhodes PG, LeBlanc MH, et al. Role of postnatal penicillin prophylaxis in prevention of neonatal group B streptococcus infection. Acta Paediatr 1999; 88:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/84\">",
"      Pyati SP, Pildes RS, Jacobs NM, et al. Penicillin in infants weighing two kilograms or less with early-onset Group B streptococcal disease. N Engl J Med 1983; 308:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/57/19354/abstract/85\">",
"      Woodgate P, Flenady V, Steer P. Intramuscular penicillin for the prevention of early onset group B streptococcal infection in newborn infants. Cochrane Database Syst Rev 2004; :CD003667.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 438 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-CBA3D06F7A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_57_19354=[""].join("\n");
var outline_f18_57_19354=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IDENTIFICATION OF COLONIZED GRAVIDAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2760920\">",
"      Culture versus risk factor-based screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4902919\">",
"      Culture-based approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4903354\">",
"      - Exceptions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4902926\">",
"      Performance of GBS cultures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4902953\">",
"      - Incidental findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4902960\">",
"      - Rapid diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factor-based approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INTRAPARTUM ANTIBIOTIC PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Indications for antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antibiotic prophylaxis for GBS is not indicated",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Antibiotic regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Patients with penicillin allergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4905148\">",
"      Timing and duration of prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      APPROACH TO THREATENED PRETERM DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4905413\">",
"      Preterm labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Early-onset GBS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2502761\">",
"      - Late-onset GBS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Missed cases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Development of antibiotic resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      GBS PROPHYLAXIS FOR OBSTETRICAL PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95981696\">",
"      Antepartum procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95981703\">",
"      Intrapartum procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      NEWBORNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3800229\">",
"      Preventive strategies after birth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3800168\">",
"      Management of newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34535601\">",
"      GUIDELINES FROM NATIONAL ORGANIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/438\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/438|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?24/50/25391\" title=\"algorithm 1\">",
"      CDC algorithm for prenatal GBS screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?2/17/2335\" title=\"algorithm 2\">",
"      CDC algorithm for GBS prophylaxis in penicillin allergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?36/22/37230\" title=\"algorithm 3\">",
"      CDC algorithm for screening for GBS in preterm labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?40/5/41054\" title=\"algorithm 4\">",
"      CDC algorithm for screening for GBS in preterm PROM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=related_link\">",
"      Group B streptococcal infection in neonates and young infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43062?source=related_link\">",
"      Group B streptococcal infection in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9621?source=related_link\">",
"      Group B streptococcus: Virulence factors and pathogenic mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2552?source=related_link\">",
"      Management of the infant whose mother has received group B streptococcal chemoprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/42/42657?source=related_link\">",
"      Patient information: Group B streptococcal disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11248?source=related_link\">",
"      Patient information: Group B streptococcus and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=related_link\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43657?source=related_link\">",
"      Urinary tract infections and asymptomatic bacteriuria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/47/15096?source=related_link\">",
"      Vancomycin dosing and serum concentration monitoring in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_57_19355="Animal dander avoid PI";
var content_f18_57_19355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F58126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F58126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tips for avoiding animal allergens (urine, saliva, or dander) in your home",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        If possible, remove animals from your home",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keep any animals outside, in the garage, or in a kennel. Keeping them out of certain rooms in the house will",
"        <strong>",
"         not",
"        </strong>",
"        remove animal allergens from your home.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        After you remove the animal, clean your home thoroughly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        If you cannot remove the animals from your home, try these steps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use an air filter with a \"HEPA filter,\" but keep in mind that air filters help only a little. Most of the animal allergens in your home are not floating in the air. Air filters remove only allergens that are floating in the air.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduce the number of things in your home where allergens can build up. Examples include carpets, fabric-covered furniture, and drapes. Replace these with bare floors, furniture that is not covered with fabric, and window blinds.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Every week, vacuum with a vacuum cleaner than has a \"HEPA filter\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If you are allergic to your dog, bathing your dog 2 times a week might help reduce your symptoms. If you are allergic to your cat, bathing your cat will probably not reduce your symptoms.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_57_19355=[""].join("\n");
var outline_f18_57_19355=null;
var title_f18_57_19356="AHA physiologic assessment CAD";
var content_f18_57_19356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    AHA scientific statement: Applications of physiologic measurements under study*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Measurement of coronary artery pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To evaluate the significance of one or more possible culprit lesions in patients with multivessel disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To evaluate ostial or distal left main lesions and ostial right lesions that are not well visualized by angiography.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To guide the treatment of serial stenoses in a single coronary artery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To determine the significance of a single treatable lesion in a diffusely diseased vessel.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To estimate prognosis after stent placement.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To assess the significance of a stenosis in patients with a recent (more than six days) myocardial infarction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To assess lesions in patients with treated unstable angina.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To assess the collateral circulation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Measurement of coronary artery flow velocity by Doppler methods",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To assess the microcirculation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To assess endothelial function.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To assess myocardial viability in patients with acute myocardial infarction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Measurement of both coronary artery pressure and Doppler coronary artery flow velocity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To assess intermediate stenosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To assess the microcirculation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To assess lesion compliance, as defined by the change in the pressure drop to velocity relationship.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Applications of physiologic measurements that have recommended during PCI by the 2005 ACC/AHA/SCAI guidelines are presented separately.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Kern, MJ, Lerman, A, Bech, JW, et al. Physiological assessment of coronary artery disease in the cardiac catheterization laboratory: a scientific statement from the American Heart Association Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology. Circulation 2006; 114:1321.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_57_19356=[""].join("\n");
var outline_f18_57_19356=null;
var title_f18_57_19357="Pretest probability of CHD";
var content_f18_57_19357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53433%7ECARD%2F64463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53433%7ECARD%2F64463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pretest probability of coronary heart disease (CHD) in patients with chest pain according to age, gender, and symptoms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Nonanginal pain",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Atypical angina",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Typical angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Men",
"       </td>",
"       <td class=\"subtitle2\">",
"        Women",
"       </td>",
"       <td class=\"subtitle2\">",
"        Men",
"       </td>",
"       <td class=\"subtitle2\">",
"        Women",
"       </td>",
"       <td class=\"subtitle2\">",
"        Men",
"       </td>",
"       <td class=\"subtitle2\">",
"        Women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30 to 39",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40 to 49",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50 to 59",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60 to 69",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        86",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     The probability values are expressed as the percent of patients with significant coronary artery disease on angiography.",
"     <span style=\"font-style:italic\">",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Combined data from Diamond GA, Forrester JS. N Engl J Med 1979; 300:1350; and from Weiner DA, Ryan TJ, McCabe CH, et al. N Engl J Med 1979; 301:230.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pretest probability of coronary heart disease (CHD) and accuracy of exercise test in the CASS population",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical history",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gender",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevalence of CHD, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        False positive, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        False negative, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Definite angina",
"       </td>",
"       <td>",
"        Male",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Definite angina",
"       </td>",
"       <td>",
"        Female",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Probable angina",
"       </td>",
"       <td>",
"        Male",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Probable angina",
"       </td>",
"       <td>",
"        Female",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonischemic chest pain",
"       </td>",
"       <td>",
"        Male",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonischemic chest pain",
"       </td>",
"       <td>",
"        Female",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The Coronary Artery Surgery Study (CASS) examined in part the pretest probability of coronary heart disease (CHD) and the accuracy of exercise testing among patients presenting with complaints of chest pain. The exercise test was considered positive when there was &ge;1 mm ST segment depression or elevation for at least 0.08 sec compared to the baseline ECG. When patients were divided into subgroups based upon gender and the quality of their chest pain complaints, the pretest probability of CHD (as determined by coronary angiography) varied between 5 and 89 percent and the false positive and negative rates of exercise testing varied between 4 and 94 and 5 and 65 percent, respectively. The higher false positive rate in women compared to men could be explained by the lower prevalence of CHD in women.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Weiner DA, Ryan TJ, McCabe CH, et al. N Engl J Med 1979; 301:230.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_57_19357=[""].join("\n");
var outline_f18_57_19357=null;
var title_f18_57_19358="Phase II induction concurrent CRT NPC";
var content_f18_57_19358=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F79686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F79686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Phase II trials of induction-concurrent chemoradiotherapy in nasopharyngeal carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Group",
"       </td>",
"       <td class=\"subtitle1\">",
"        n",
"       </td>",
"       <td class=\"subtitle1\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        RT",
"       </td>",
"       <td class=\"subtitle1\">",
"        Induction regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Concurrent regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Local control",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Distant control",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        OS",
"        <br/>",
"        (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Rischin, et al",
"        </strong>",
"        (2002)",
"        <br/>",
"        Australia",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        II-IVB",
"       </td>",
"       <td>",
"        60 Gy",
"       </td>",
"       <td>",
"        ECF x 3",
"       </td>",
"       <td>",
"        Cisplatin 75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        every five weeks times two",
"       </td>",
"       <td class=\"centered\">",
"        Four-year",
"        <br/>",
"        97",
"       </td>",
"       <td class=\"centered\">",
"        94",
"       </td>",
"       <td class=\"centered\">",
"        90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Oh, et al",
"        </strong>",
"        (2003)",
"        <br/>",
"        Chicago",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        II-IVB",
"       </td>",
"       <td>",
"        Split RT, 70 Gy",
"       </td>",
"       <td>",
"        PFL-IFN x 3",
"       </td>",
"       <td>",
"        FHX times seven (week on, week off)",
"        <br/>",
"        (5FU + hydroxyurea)",
"       </td>",
"       <td class=\"centered\">",
"        Five-year",
"        <br/>",
"        93",
"       </td>",
"       <td class=\"centered\">",
"        92",
"       </td>",
"       <td class=\"centered\">",
"        77",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Chan, et al",
"        </strong>",
"        (2004)",
"        <br/>",
"        Hong Kong",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        III-IVB",
"       </td>",
"       <td>",
"        66 Gy",
"       </td>",
"       <td>",
"        TC x 2",
"       </td>",
"       <td>",
"        Cisplatin 40 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        <br/>",
"        Weekly times six to eight",
"       </td>",
"       <td class=\"centered\">",
"        Two-year",
"        <br/>",
"        90*",
"       </td>",
"       <td class=\"centered\">",
"        81*",
"       </td>",
"       <td class=\"centered\">",
"        92",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Al-Amro, et al",
"        </strong>",
"        (2005)",
"        <br/>",
"        Saudi Arabia",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        II-IVB",
"       </td>",
"       <td>",
"        66 Gy",
"       </td>",
"       <td>",
"        Cisplatin + Epirubicin x 2",
"       </td>",
"       <td>",
"        Cisplatin 25 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        <br/>",
"        Days 1 to 4 every three weeks times three",
"       </td>",
"       <td class=\"centered\">",
"        Three-year",
"        <br/>",
"        68",
"       </td>",
"       <td class=\"centered\">",
"        74",
"       </td>",
"       <td class=\"centered\">",
"        71",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Johnson, et al",
"        </strong>",
"        (2005)",
"        <br/>",
"        M D Anderson",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        II-IVB",
"       </td>",
"       <td>",
"        70 Gy",
"       </td>",
"       <td>",
"        PF x 3",
"       </td>",
"       <td>",
"        PF times two on weeks six to seven (chemo boost)",
"       </td>",
"       <td class=\"centered\">",
"        Three-year",
"        <br/>",
"        75*",
"       </td>",
"       <td class=\"centered\">",
"        89*",
"       </td>",
"       <td class=\"centered\">",
"        78",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Lee, et al",
"        </strong>",
"        (2005)",
"        <br/>",
"        Hong Kong",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        IVA-B",
"       </td>",
"       <td>",
"        AF, 70 Gy",
"       </td>",
"       <td>",
"        PF x 3",
"       </td>",
"       <td>",
"        Cisplatin 100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        <br/>",
"        Every three weeks times two to three",
"       </td>",
"       <td class=\"centered\">",
"        Three-year",
"        <br/>",
"        77",
"       </td>",
"       <td class=\"centered\">",
"        75",
"       </td>",
"       <td class=\"centered\">",
"        71",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Yau, et al",
"        </strong>",
"        (2006)",
"        <br/>",
"        Hong Kong",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        IVA-B",
"       </td>",
"       <td>",
"        AF, 70 Gy",
"       </td>",
"       <td>",
"        PG x 3",
"       </td>",
"       <td>",
"        Cisplatin 100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        <br/>",
"        Every three weeks times two to three",
"       </td>",
"       <td class=\"centered\">",
"        Three-year",
"        <br/>",
"        78",
"       </td>",
"       <td class=\"centered\">",
"        76",
"       </td>",
"       <td class=\"centered\">",
"        76",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Ferari, et al",
"        </strong>",
"        (2008)",
"        <br/>",
"        Italy",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        IIB-IVB",
"       </td>",
"       <td>",
"        3D-CRT, 70 Gy",
"       </td>",
"       <td>",
"        PF x 3",
"       </td>",
"       <td>",
"        Cisplatin (P)",
"        <br/>",
"        Every three weeks times three",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        Three-year PFS",
"        <br/>",
"        54",
"       </td>",
"       <td class=\"centered\">",
"        Three-year",
"        <br/>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Airoldi, et al",
"        </strong>",
"        (2009)",
"        <br/>",
"        Italy",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        III-IVB",
"       </td>",
"       <td>",
"        3D-CRT, 70 Gy",
"       </td>",
"       <td>",
"        Cisplatin-Epirubicin x 3",
"       </td>",
"       <td>",
"        Cisplatin (P)",
"        <br/>",
"        Every three weeks times three",
"       </td>",
"       <td class=\"centered\">",
"        Five-year",
"        <br/>",
"        70",
"       </td>",
"       <td class=\"centered\">",
"        75",
"       </td>",
"       <td class=\"centered\">",
"        Five-year",
"        <br/>",
"        77",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Airoldi, et al",
"        </strong>",
"        (2010)",
"        <br/>",
"        Italy",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        III-IVB",
"       </td>",
"       <td>",
"        3D-CRT, 70 Gy",
"       </td>",
"       <td>",
"        Carboplatin-Paclitaxel x 3",
"       </td>",
"       <td>",
"        Carboplatin-Paclitaxel",
"        <br/>",
"        Weekly",
"       </td>",
"       <td class=\"centered\">",
"        Five-year",
"        <br/>",
"        90",
"       </td>",
"       <td class=\"centered\">",
"        85",
"       </td>",
"       <td class=\"centered\">",
"        Five-year",
"        <br/>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Bae, et al",
"        </strong>",
"        (2010)",
"        <br/>",
"        Korea",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        III-IVB",
"       </td>",
"       <td>",
"        68.4 Gy (1.8-2 Gy)",
"       </td>",
"       <td>",
"        TPF x 3",
"       </td>",
"       <td>",
"        Cisplatin (P)",
"        <br/>",
"        Every three weeks times three",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        Three-year PFS",
"        <br/>",
"        76",
"       </td>",
"       <td class=\"centered\">",
"        Three-year",
"        <br/>",
"        86",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Kong, et al",
"        </strong>",
"        (2010)",
"        <br/>",
"        Fudan, China",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        III-IVB",
"       </td>",
"       <td>",
"        3D-CRT or IMRT",
"        <br/>",
"        70-76 Gy",
"       </td>",
"       <td>",
"        TPF x 3",
"       </td>",
"       <td>",
"        Cisplatin (P) times seven",
"       </td>",
"       <td class=\"centered\">",
"        One-year",
"        <br/>",
"        98",
"       </td>",
"       <td class=\"centered\">",
"        96",
"       </td>",
"       <td class=\"centered\">",
"        One-year",
"        <br/>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Bossi, et al",
"        </strong>",
"        (2011)",
"        <br/>",
"        Italy",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        III-IVB",
"       </td>",
"       <td>",
"        IMRT",
"        <br/>",
"        66-70 Gy",
"       </td>",
"       <td>",
"        TPF x 2-3",
"       </td>",
"       <td>",
"        Cisplatin (P)",
"        <br/>",
"        Every three weeks times three",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        Three-year PFS",
"        <br/>",
"        79",
"       </td>",
"       <td class=\"centered\">",
"        Three-year",
"        <br/>",
"        87",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AF: accelerated fractionation; CRT: chemoradiotherapy; ECF: epirubicin, cisplatin, 5-fluorouracil; Gy: Gray; IMRT: intensity-modulated radiation therapy; OS: overall survival; PF: cisplatin, 5-fluorouracil; PFL-IFN: cisplatin, 5-fluorouracil, leucovorin, interferon; PFS: progression-free survival; PG: cisplatin, 5-fluorouracil; TC: paclitaxel, carboplatin; TPF: paclitaxel, cisplatin, 5-fluorouracil.",
"     <br>",
"      * Crude rate.",
"      <br/>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_57_19358=[""].join("\n");
var outline_f18_57_19358=null;
var title_f18_57_19359="Automated platelet counting low";
var content_f18_57_19359=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F80032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F80032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Comparison between automated optical and immunologic platelet counts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 468px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This graph depicts simultaneously-obtained automated platelet counts using an optical method (y-axis) and an immunologic method (anti-CD61, y-axis) for counts in the range from zero to 30,000 platelets/&micro;L. The least squares best-fit line for the data points is shown as the red line, while the 95 percent confidence limits are shown by the two dashed blue lines. Note that the majority of the data points well outside of the 95 percent confidence limits are above the best-fit line, suggesting that the optical method is more prone to overestimate platelet counts than the immunologic method in this range.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Kunz, D, et al. Br J Haematol 2001; 112:584.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_57_19359=[""].join("\n");
var outline_f18_57_19359=null;
   